Movano (MOVE) 10-K30 Mar 232022 FY Annual reportFinancial data

Company Profile

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
Document And Entity Information - USD ($)	Dec. 31, 2022	Mar. 23, 2023	Jun. 30, 2022
Document Information Line Items
Entity Registrant Name	MOVANO INC.
Trading Symbol	MOVE
Document Type	10-K
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding		41,310,108
Entity Public Float			$ 57,424,946
Amendment Flag	false
Entity Central Index Key	0001734750
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Dec. 31, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	FY
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
ICFR Auditor Attestation Flag	false
Document Annual Report	true
Document Transition Report	false
Entity File Number	001-40254
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	82-4233771
Entity Address, Address Line One	6800 Koll Center Parkway
Entity Address, City or Town	Pleasanton
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	94566
City Area Code	(415)
Local Phone Number	651-3172
Title of 12(b) Security	Common Stock, par value $0.0001 per share
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Auditor Firm ID	659
Auditor Name	Moss Adams LLP
Auditor Location	San Francisco

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 10,759	$ 17,675
Short-term investments		15,921
Payroll tax credit, current portion	379	166
Prepaid expenses and other current assets	508	1,296
Total current assets	11,646	35,058
Property and equipment, net	443	529
Payroll tax credit, noncurrent portion	667	630
Other assets	487	48
Total assets	13,243	36,265
Current liabilities:
Accounts payable	557	311
Other current liabilities	4,421	2,907
Total current liabilities	4,978	3,218
Early exercised stock option liability	136	281
Other noncurrent liabilities	214	36
Total noncurrent liabilities	350	317
Total liabilities	5,328	3,535
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 shares authorized at December 31, 2022 and 2021; no shares issued and outstanding at December 31, 2022 and 2021
Common stock, $0.0001 par value, 75,000,000 shares authorized at December 31, 2022 and 2021; 33,659,460 and 32,772,060 shares issued and outstanding at December 31, 2022 and 2021, respectively	3	3
Additional paid-in capital	103,009	97,506
Accumulated other comprehensive loss		(11)
Accumulated deficit	(95,097)	(64,768)
Total stockholders’ equity	7,915	32,730
Total liabilities and stockholders’ equity	$ 13,243	$ 36,265

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Dec. 31, 2022	Dec. 31, 2021
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, par value (in Dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized	75,000,000	75,000,000
Common stock, shares issued	33,659,460	33,659,460
Common stock, shares outstanding	32,772,060	32,772,060

Consolidated Statements of Oper

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
OPERATING EXPENSES:
Research and development	$ 18,994	$ 13,427
General and administrative	11,468	6,376
Total operating expenses	30,462	19,803
Loss from operations	(30,462)	(19,803)
Other income (expense), net:
Interest expense		(883)
Change in fair value of warrant liability		(1,581)
Change in fair value of derivative liability		121
Forgiveness of Paycheck Protection Program Loan		351
Interest and other income, net	133	22
Other income (expense), net	133	(1,970)
Net loss	(30,329)	(21,773)
Other comprehensive loss:
Change in unrealized loss on available-for-sale securities		(11)
Total comprehensive loss	$ (30,329)	$ (21,784)
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (0.92)	$ (0.92)
Weighted average shares used in computing net loss per share attributable to common stockholders, basic and diluted (in Shares)	33,025,721	26,298,032
Accretion and dividends on redeemable convertible preferred stock		$ (2,489)
Net loss attributable to common stockholders	$ (30,329)	$ (24,262)

Consolidated Statements of Op_2

Consolidated Statements of Operations and Comprehensive Loss (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Net loss per share attributable to common stockholders, diluted (in Dollars per share)	$ (0.91)	$ (0.92)
Weighted average shares used in computing net loss per share attributable to common stockholders, diluted (in Shares)	33,000,166	26,298,032

Consolidated Statements of Rede

Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity (Deficit) - USD ($) $ in Thousands	Series A Redeemable Convertible Preferred Stock	Series B Redeemable Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2020	$ 13,856	$ 18,962	$ 1			$ (40,881)	$ (40,880)
Balance (in Shares) at Dec. 31, 2020	2,692,253	4,942,319	6,393,069
Stock-based compensation				1,854			1,854
Accretion of Series A and Series B redeemable convertible preferred stock	686	1,803		(2,489)			(2,489)
Accretion of Series A and Series B redeemable convertible preferred stock (in Shares)
Issuance of common stock upon exercise of options				49			49
Issuance of common stock upon exercise of options (in Shares)			134,541
Vesting of early exercised stock options				163			163
Vesting of early exercised stock options (in Shares)
Reclassification of negative additional paid-in capital				2,114		(2,114)
Conversion of preferred stock to common stock upon initial public offering	$ (14,542)	$ (20,765)	$ 1	35,306			35,307
Conversion of preferred stock to common stock upon initial public offering (in Shares)	(2,692,253)	(4,942,319)	11,436,956
Issuance of common stock upon initial public offering, net of issuance costs			$ 1	41,924			41,925
Issuance of common stock upon initial public offering, net of issuance costs (in Shares)			9,775,000
Issuance of underwriter warrants upon initial public offering				2,349			2,349
Issuance of underwriter warrants upon initial public offering (in Shares)
Reclassification of liability-classified warrants upon initial public offering				3,130			3,130
Reclassification of liability-classified warrants upon initial public offering (in Shares)
Conversion of convertible promissory notes and accrued interest upon initial public offering				12,550			$ 12,550
Conversion of convertible promissory notes and accrued interest upon initial public offering (in Shares)			5,015,494				11,436,956
Issuance of common stock for nonemployee services				85			$ 85
Issuance of common stock for nonemployee services (in Shares)			17,000
Beneficial conversion feature upon issuance of convertible promissory note				471			471
Beneficial conversion feature upon issuance of convertible promissory note (in Shares)
Other comprehensive income (loss)					(11)		(11)
Other comprehensive income (loss) (in Shares)
Net loss						(21,773)	(21,773)
Balance at Dec. 31, 2021			$ 3	97,506	(11)	(64,768)	32,730
Balance (in Shares) at Dec. 31, 2021			32,772,060
Stock-based compensation				3,096			3,096
Stock-based compensation (in Shares)
Issuance of common stock				2,231			$ 2,231
Issuance of common stock (in Shares)			810,400				17,000
Issuance of common stock upon exercise of options				31			$ 31
Issuance of common stock upon exercise of options (in Shares)			77,000
Vesting of early exercised stock options				145			145
Vesting of early exercised stock options (in Shares)
Issuance of underwriter warrants upon initial public offering
Beneficial conversion feature upon issuance of convertible promissory note (in Shares)
Other comprehensive income (loss)					11		11
Other comprehensive income (loss) (in Shares)
Net loss						(30,329)	(30,329)
Balance at Dec. 31, 2022			$ 3	$ 103,009		$ (95,097)	$ 7,915
Balance (in Shares) at Dec. 31, 2022			33,659,460

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (30,329)	$ (21,773)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	147	74
Forgiveness of Paycheck Protection Program loan		(351)
Stock-based compensation	3,096	1,854
Noncash lease expense	(13)
Accretion of debt discount on convertible promissory notes		772
Accrued interest on convertible promissory notes		115
Accretion of discount on short-term investments	103	202
Non-employee services under convertible promissory notes		50
Compensation of non-employee services upon issuance of common stock		74
Change in fair value of derivative liability		(121)
Change in fair value of warrant liability		1,581
Loss on disposal of property and equipment	44
Changes in operating assets and liabilities:
Payroll tax credit	(250)	(162)
Prepaid expenses and other current assets	788	(802)
Other assets	(50)	(38)
Accounts payable	246	65
Other current and noncurrent liabilities	1,316	2,277
Net cash used in operating activities	(24,902)	(16,183)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property and equipment	(105)	(565)
Purchases of short-term investments		(23,633)
Maturities of short-term investments	15,829	7,499
Net cash provided by/(used in) investing activities	15,724	(16,699)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of common stock - net of issuance costs	2,231	76
Issuance of common stock upon exercise of stock options	31
Proceeds from issuance of shares upon Initial Public Offering - net of issuance costs		44,771
Net cash provided by financing activities	2,262	44,847
Net increase/(decrease) in cash and cash equivalents	(6,916)	11,965
Cash and cash equivalents at beginning of period	17,675	5,710
Cash and cash equivalents at end of period	10,759	17,675
NONCASH INVESTING AND FINANCING ACTIVITIES:
Accretion of Series A redeemable convertible preferred stock		686
Accretion of Series B redeemable convertible preferred stock		1,803
Conversion of preferred stock to common stock upon initial public offering		35,307
Reclassification of liability-classified warrants upon initial public offering		3,130
Issuance of underwriter warrants upon initial public offering		2,349
Issuance of convertible promissory notes for completion of non-employee services		500
Beneficial conversion feature upon issuance of convertible promissory note		471
Conversion of convertible promissory notes upon initial public offering		12,550
Vesting of common stock issued upon early exercise	145	136
Issuance of common stock for non-employee services		11
Reclassification of deferred offering costs upon initial public offering		497
[Property and equipment purchases in account payable]	$ 19

Business Organization, Nature o

Business Organization, Nature of Operations	12 Months Ended
Business Organization, Nature of Operations	Dec. 31, 2022
Business Organization, Nature of Operations [Abstract]
BUSINESS ORGANIZATION, NATURE OF OPERATIONS	Note 1 – Business Organization, Nature of Operations Movano Inc., dba Movano Health (the “Company”, “Movano”, “Movano Health”, “we”, “us” or “our”), was incorporated in Delaware on January 30, 2018 as Maestro Sensors Inc. and changed its name to Movano Inc. on August 3, 2018. The Company is in the development-stage and is developing a platform to deliver purpose-driven healthcare solutions at the intersection of medical and consumer devices. Movano is on a mission to make medical grade data more accessible and actionable for all. The Company’s solutions are being developed to provide vital health information, including heart rate, HRV, sleep, respiration rate, temperature, SpO 2 On April 28, 2021, the Company established Movano Ireland Limited, organized under the laws of Ireland, as a wholly owned subsidiary of the Company. Operations and activity at the wholly owned subsidiary were not significant for the years ended December 31, 2022 and 2021, respectively. Since inception, the Company has engaged in only limited research and development of product candidates and underlying technology. As of December 31, 2022, the Company had not yet completed the development of its product and had not yet recorded any revenues. In December 2019, a novel coronavirus and the resulting disease (“COVID-19”) was reported, and in January 2020, the World Health Organization (“WHO”) declared it a Public Health Emergency of International Concern. In February 2020, the WHO raised its assessment of the COVID-19 threat from high to very high at a global level due to the continued increase in the number of cases and affected countries, and in March 2020, the WHO characterized COVID-19 as a pandemic. The Company continues to evaluate the impact of the COVID-19 pandemic and has concluded that while it is reasonably possible that the virus could have a negative effect on the Company’s consolidated financial position or consolidated results of operations, the specific impact is not readily determinable as of the date of these consolidated financial statements. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty. The Company’s Registration Statement on Form S-1, as amended (Reg. No. 333-252671), was declared effective by the U.S. Securities and Exchange Commission (the “SEC”) on March 23, 2021. The registration statement registered the securities offered in the Company’s initial public offering (“IPO”). In the IPO, the Company sold 9,775,000 shares of common stock at a price to the public of $5.00 per share, including the full exercise of the underwriters’ option to purchase additional shares. The IPO closed on March 25, 2021 and the underwriters exercised their overallotment option as of March 25, 2021, as a result of which the Company raised net proceeds of $44.3 million after deducting $3.3 million in underwriting discounts, commissions, and expenses and $1.3 million in offering expenses paid by the Company. National Securities Corporation (“NSC”) was the underwriter for the IPO, and also received a warrant related to the IPO, which is discussed in Note 11. No portion of the net proceeds from the IPO were used for payments made by the Company to its directors or officers or persons owning ten percent or more of its common stock or to their associates, or to the Company’s affiliates, other than payments in the ordinary course of business to officers for salaries and to nonemployee directors as compensation for board or board committee service. On February 6, 2023, the Company completed a $7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter's overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of $1.57. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant was $1.40. The net proceeds from the offering were approximately $6.85 million (See Note 16). The Company has incurred losses from operations and has generated negative cash flows from operating activities since inception. The Company expects to continue to incur net losses for the foreseeable future as it continues the development of its technology. The Company’s ultimate success depends on the outcome of its research and development and commercialization activities, for which it expects to incur additional losses in the future. Through December 31, 2022, the Company has relied primarily on the proceeds from equity offerings to finance its operations. Through December 31, 2022, the Company has received proceeds of approximately $2.2 million from an at-the-market issuance program, and an aggregate offering price amount of approximately $47.7 million remains available to be issued. (See Note 10.) The Company expects to require additional financing to fund its future planned operations, including research and development and commercialization of its products. The Company will likely raise additional capital through the issuance of equity, borrowings, or strategic alliances with partner companies. However, if such financing is not available at adequate levels, the Company would need to reevaluate its operating plans. Liquidity and Going Concern The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred significant losses and has an accumulated deficit of $95.1 million as of December 31, 2022. The Company anticipates incurring additional losses until such time, if ever, that it can generate significant sales. The Company’s existence is dependent upon management’s ability to obtain additional funding sources. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. Adequate additional financing may not be available to the Company on acceptable terms, or at all. If the Company is unable to raise additional capital and/or enter into strategic alliances when needed or on attractive terms, it would be forced to delay, reduce, or eliminate its product or any commercialization efforts. There can be no assurance that the Company’s efforts will result in the resolution of the Company’s liquidity needs. The accompanying consolidated financial statements do not include any adjustments that might result should the Company be unable to continue as a going concern.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2022
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	Note 2 – Summary of Significant Accounting Policies Basis of Presentation The Company has prepared the accompanying consolidated financial statements in accordance with GAAP. Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, the valuation of the embedded redemption derivative liability and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer. Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company classifies all marketable securities for use in current operations, even if the security matures beyond 12 months, and presents them as short-term investments in the consolidated balance sheets. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for the purchased marketable securities as available-for-sale. After considering the Company’s capital preservation objectives, as well as its liquidity requirements, the Company may sell securities prior to their stated maturities. The Company carries its available-for-sale short-term investments at fair value. The Company reports the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for unrealized losses determined to be credit-related, which are recorded as other income (expense), net in the consolidated statements of operations and comprehensive loss and reports an allowance for credit losses in short-term investments on the balance sheet, if any. The Company determines any realized gains or losses on the sale of short-term investments on a specific identification method and records such gains and losses as a component of other income (expense), net. Interest earned on cash, cash equivalents, and short-term investments is recorded in interest and other income, net in the accompanying consolidated statements of operations and comprehensive loss and was $277,000 and insignificant during the years ended December 31, 2022 and 2021. The Company’s investment policy only allows purchases of high credit quality instruments and provides guidelines on concentrations and credit quality to ensure minimum risk of loss. The Company evaluates whether the unrealized loss on available-for-sale short-term investments is the result of the credit worthiness of the securities it held, or other non-credit-related factors such as liquidity by reviewing a number of factors such as the implied yield of the corporate note based on the market price, the nature of the invested entity’s business or industry, market capitalization relative to debt, changes in credit ratings, and the market prices of the instruments subsequent to the period end. Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. All cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts and institutional money market funds. The amounts deposited in the money market accounts exceed federally insured limits. Further, the Company has amounts in excess of federally insured limits as of December 31, 2022 at one financial institution that totaled approximately $2.3 million. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. The Company has no financial instruments with off-balance sheet risk of loss. Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of prepaid expenses, other current receivables, and deferred offering costs, which consist of legal, accounting, filing and other fees related to the IPO that were capitalized prior to the IPO. The deferred offering costs were offset against proceeds from the IPO within additional paid-in capital upon the effective date of the IPO. Software Development Costs Costs related to software development are included in research and development expense until the point that technological feasibility is reached, which, for the Company’s product, will be shortly before the product is released to manufacturing. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the product. During the years ended December 31, 2022 and 2021, no development costs were capitalized. Impairment of Long-Lived Assets The Company reviews the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount. Paycheck Protection Program Loan The Company accounted for funds received from the Paycheck Protection Program as a financial liability with interest accrued and expensed over the term of the loan under the effective interest method. The loan remained recorded as a liability until the Company was legally released from the liability. The amount that was ultimately forgiven by the lender was recognized in the consolidated statement of operations and comprehensive loss as a gain on extinguishment. Convertible Financial Instruments The Company bifurcates embedded redemption and conversion options from their host instruments and accounts for them as freestanding derivative financial instruments at fair value if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption. From time to time, the Company issues convertible financial instruments to nonemployees in payment for services that are provided. Until the services are completely rendered, the Company will expense the principal and any interest earned prior to the service completion to the representative expense account for the services performed and will record a noncurrent liability for the expected amount of the principal balance. Upon completion of the services, the Company will reclassify the noncurrent liability balance to the balance of an outstanding convertible financial instrument and assess the embedded redemption and conversion options that are applicable at that time. Beneficial Conversion Feature If the conversion feature of conventional convertible promissory notes provides for a rate of conversion that is below fair value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount and as additional paid-in capital on the consolidated balance sheet. In those circumstances, the convertible debt is recorded net of the discount related to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method. Redeemable Convertible Preferred Stock The Company records all shares of redeemable convertible preferred stock at their respective issuance price less issuance costs on the dates of issuance. Under certain circumstances the Company would have been required to redeem the Series A and Series B redeemable convertible preferred stock unless an IPO had been consummated prior to April 1, 2021, or an extension or waiver was obtained upon approval of a majority of the holders of such preferred stock. As the preferred stock became redeemable due to the passage of time, the Company considered the preferred stock to be redeemable as of April 1, 2021. The Company recorded the accretion of the Series A and B preferred stock balances to their respective redemption amounts using the effective interest method. The redeemable convertible preferred stock is presented outside of stockholders’ deficit on the consolidated balance sheet as of December 31, 2020. Upon the IPO, the redeemable convertible preferred stock converted into 11,436,956 shares of common stock. Comprehensive Loss Comprehensive loss is the change in stockholders’ equity (deficit) from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company’s other comprehensive loss is comprised of unrealized gains and losses on investments in available-for-sale securities. Research and Development Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on the Company’s behalf. Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur. Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses. Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the year ended December 31, 2022 and 2021. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs. Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Series A and B redeemable convertible preferred stock and cumulative dividends on Series A and B redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive. Recently Adopted Accounting Pronouncements The Company adopted FASB’s ASU No. 2016-02, Leases In addition, the Company elected the package of practical expedients and other expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carry forward the historical lease classification and not to restate the comparative periods prior to the adoption and to combine lease and non-lease components for all asset classes. The Company made an accounting policy election not to recognize right of use assets and lease liabilities for leases with a lease term of 12 months or less, including renewal options that are reasonably certain to be exercised, that also do not include an option to purchase the underlying asset that is reasonably certain of exercise. Instead, lease payments for these leases are recognized as lease expense on a straight-line basis over the lease term. The disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under the previous accounting guidance. The adoption of the new standard did not have a material impact on the Company’s results of operations or cash flows. Operating lease right of use (“ROU”) assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Adoption of the new standard resulted in the recording of operating lease liabilities of $429,000 and ROU assets of $380,000 as of January 1, 2022. The difference between the ROU assets and lease liabilities represents the net book value of deferred rent recognized as of December 31, 2021, which was adjusted against the ROU asset upon adoption. The ROU asset is included in other assets on the Company’s consolidated balance sheet. At adoption, operating lease liabilities of $166,000 and $263,000, respectively, were included in other current liabilities and other noncurrent liabilities on the Company’s consolidated balance sheet. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in research and development expenses and sales, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

Fair Value Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2022
Fair Value Measurements [Abstract]
FAIR VALUE MEASUREMENTS	Note 3 – FAIR VALUE MEASUREMENTS Financial assets and liabilities are recorded at fair value. The Company uses a three-level hierarchy, which prioritizes, within the measurement of fair value, the use of market-based information over entity-specific information for fair value measurements based on the nature of inputs used in the valuation of an asset or liability as of the measurement date. Fair value focuses on an exit price and is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The inputs or methodology used for valuing financial instruments are not necessarily an indication of the risk associated with investing in those financial instruments. A three-tier fair value hierarchy is used to prioritize the inputs in measuring fair value as follows: Level 1 Quoted prices in active markets for identical assets or liabilities. Level 2 Quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable, either directly or indirectly. Level 3 Significant unobservable inputs that cannot be corroborated by market data. The Company measures its cash equivalents, short-term investments and derivative financial instruments at fair value. The Company classifies its cash equivalents and short-term investments within Level 1 or Level 2 because the Company values these investments using quoted market prices or alternative pricing sources and models utilizing market observable inputs. The fair value of the Company’s Level 1 financial assets is based on quoted market prices of the identical underlying security. The fair value of the Company’s Level 2 financial assets is based on inputs that are directly or indirectly observable in the market, including the readily-available pricing sources for the identical underlying security that may not be actively traded. The asset’s or liability’s fair value measurement level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Changes in fair value measurements categorized within Level 3 of the fair value hierarchy are analyzed each period based on changes in estimates or assumptions and recorded as appropriate. The carrying amounts of prepaid expenses, payroll tax credit, accounts payable and accrued liabilities approximate fair value due to the short-term nature of these instruments. The following tables provide a summary of the assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2022 and 2021 (in thousands). December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 8,171 $ 8,171 $ — $ — Total cash equivalents $ 8,171 $ 8,171 $ — $ — December 31, 2021 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 16,830 $ 16,830 $ — $ — Total cash equivalents $ 16,830 $ 16,830 $ — $ — Short-term investments: Certificates of deposit $ 250 $ — $ 250 $ — Commercial paper 2,210 — 2,210 — Corporate notes 12,024 — 12,024 — Municipal bonds 1,437 — 1,437 — Total short-term investments $ 15,921 $ — $ 15,921 $ —

Cash, Cash Equivalents and Shor

Cash, Cash Equivalents and Short-Term Investments	12 Months Ended
Cash, Cash Equivalents and Short-Term Investments	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS	Note 4 – CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS Cash, cash equivalents and short-term investments consist of the following (in thousands): December 31, 2022 2021 Cash and cash equivalents: Cash $ 2,588 $ 845 Money market funds 8,171 16,830 Total cash and cash equivalents $ 10,759 $ 17,675 Short-term investments: Certificates of deposit $ — $ 250 Commercial paper — 2,210 Corporate notes — 12,024 Municipal bonds — 1,437 Total short-term investments $ — $ 15,921 The following table summarizes the unrealized gains and losses related to short-term investments classified as available-for-sale on the Company’s consolidated balance sheet at December 31, 2021 (in thousands): December 31, 2021 Amortized Gross Gross Aggregate Short-term investments: Certificates of deposit $ 250 $ — $ — $ 250 Commercial paper 2,210 — — 2,210 Corporate notes 12,035 — (11 ) 12,024 Municipal bonds 1,437 — — 1,437 Total short-term investments $ 15,932 $ — $ (11 ) $ 15,921 As of December 31, 2022, the Company does not have any remaining available-for-sale short-term investments. No sales of available-for-sale short-term investments occurred during the years ended December 31, 2022 and 2021, respectively.

Property and Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2022
Property and Equipment [Abstract]
PROPERTY AND EQUIPMENT	Note 5 – Property and Equipment Property and equipment, net, as of December 31, 2022 and 2021, consisted of the following (in thousands): December 31, 2022 2021 Office equipment and furniture $ 263 $ 237 Software 131 115 Test equipment 277 278 Total property and equipment 671 630 Less: accumulated depreciation (228 ) (101 ) Total property and equipment, net $ 443 $ 529 Total depreciation and amortization expense related to property and equipment for the years ended December 31, 2022 and 2021 was approximately $147,000 and $74,000, respectively.

Other Current Liabilities

Other Current Liabilities	12 Months Ended
Other Current Liabilities	Dec. 31, 2022
Other Current Liabilities [Abstract]
OTHER CURRENT LIABILITIES	Note 6 – Other Current Liabilities Other current liabilities as of December 31, 2022 and 2021 consisted of the following (in thousands): December 31, 2022 2021 Accrued compensation $ 2,708 $ 2,211 Accrued severance payment 517 — Accrued research and development 536 289 Accrued vacation 243 276 Lease liabilities, current portion 212 — Other 205 131 Total other current liabilities $ 4,421 $ 2,907

Paycheck Protection Program Loa

Paycheck Protection Program Loan	12 Months Ended
Paycheck Protection Program Loan	Dec. 31, 2022
Paycheck Protection Program Loan [Abstract]
PAYCHECK PROTECTION PROGRAM LOAN	NOTE 7 – PAYCHECK PROTECTION PROGRAM LOAN The Paycheck Protection Program (“PPP”) was established under the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) and is administered by the U.S. Small Business Administration (“SBA”). On April 23, 2020, the Company entered into a promissory note with Silicon Valley Bank evidencing an unsecured loan in the aggregate amount of approximately $351,000 under the PPP (the “PPP Loan”). The interest rate on the PPP Loan was 1.00% and the term was two years, with a deferral of payments for ten months from the date of origination. On May 7, 2020, the Company elected to repay the PPP loan in full until further guidance was provided by the SBA on the loan origination and eligibility requirements. On May 27, 2020, the Company entered into a promissory note with Silicon Valley Bank evidencing an unsecured loan in the aggregate amount of approximately $351,000, with all other terms the same as the prior loan. Beginning eleven months from the date of the PPP Loan, the Company was required to make monthly payments of principal and interest. The promissory note evidencing the PPP Loan contained customary events of default relating to, among other things, payment defaults or breaching the terms of the PPP Loan documents. The occurrence of an event of default may result in the repayment of all amounts outstanding, collection of all amounts owing from the Company, or filing suit and obtaining judgment against the Company. The PPP Loan was repayable at any time by the Company without prepayment penalties. Funds from the PPP Loan could be used for payroll costs, costs used to continue group health care benefits, mortgage payments, rent, utilities, and interest on other debt obligations, if those debt obligations were incurred before February 15, 2020. The Company used the entire PPP Loan amount for qualifying expenses. Under the terms of the CARES Act, PPP loan recipients can apply for and be granted forgiveness for all or a portion of the loan granted under the PPP. Such forgiveness will be determined, subject to limitations, based on the use of loan proceeds for qualifying expenses. On May 28, 2021, the Company received full loan forgiveness for obligations related to the PPP loan. The Company accounted for the PPP loan as debt, and the loan forgiveness was accounted for as a debt extinguishment. The amount of loan and interest forgiven is recognized as a gain upon debt extinguishment and is reported in the accompanying consolidated statement of operations and comprehensive loss for the year ended December 31, 2021.

Convertible Promissory Notes

Convertible Promissory Notes	12 Months Ended
Convertible Promissory Notes	Dec. 31, 2022
Convertible Promissory Notes [Abstract]
CONVERTIBLE PROMISSORY NOTES	NOTE 8 – CONVERTIBLE PROMISSORY NOTES On various dates between February 2020 and December 2020, the Company received total proceeds of approximately $11.8 million from the issuance of subordinated convertible promissory notes (“Convertible Notes”) to investors. The Convertible Notes accrued interest at 4% per year and the principal balance of the Convertible Notes, plus all accrued interest would have been due on February 28, 2022 (the “Maturity Date”). The Convertible Notes were convertible upon the occurrence of certain events, including upon a change in control or a next equity financing. The conversion features are described as follows: Conversion Event Description Conversion Price Automatic Conversion – Next Qualified Equity Financing Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Qualified Equity Financing closing. Automatic Conversion – Change of Control (defined as consolidation or merger of the Company or transfer of a majority of share ownership or disposition of substantially all assets of the Company) If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control. Automatic Conversion – Maturity Date If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date. Automatic Conversion – IPO If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of the Common Stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO. Conversion Event Description Conversion Price Optional Conversion If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect. An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing. As part of the Convertible Note financing, the Company agreed to issue subordinated convertible promissory notes to nonemployees in exchange for services totaling $747,000. As of December 31, 2020, Convertible Notes totaling approximately $247,000 were issued to nonemployees in exchange for services. As of December 31, 2020, future services of $500,000 of the original $747,000 had not been fully completed. A portion of those services that had been completed were recorded as a component of other noncurrent liabilities of $150,000 at December 31, 2020. During the three months ended March 31, 2021, additional nonemployee services of $50,000 were completed, which were recorded as a component of other noncurrent liabilities. In connection with the IPO, a Convertible Note for $500,000 was issued for nonemployee services and the $300,000 of the nonemployee services that remained to be completed was recorded in prepaid assets and other current expenses on the consolidated balance sheet. The Company calculated a BCF of approximately $500,000 upon the issuance of this Convertible Note. In connection with the Convertible Notes, the Company issued 10,000 and 204,500 warrants to purchase common stock, to a noteholder and its brokers, respectively. The warrants have a five-year life and are initially exercisable into common stock at $2.97 per share. (See Note 11 – Common Stock Warrants for fair value computation and discussion of the change in the exercise price). During March 2021, 42,220 of these warrants to purchase common stock were cancelled. Issuance costs and commissions to brokers to obtain the Convertible Notes were recorded as a debt discount in the amount of approximately $83,000 and $612,000, respectively. The Company determined that the terms that would result in Convertible Notes automatically converting at (i) 80% of the lowest per-share selling price of the stock sold by the Company in the Next Qualified Equity Financing or (ii) 80% of the lowest per-share selling price of the Conversion Stock sold by the Company in an IPO are deemed a redemption feature. The Company also concluded that those redemption features require bifurcation from the Convertible Notes and subsequent accounting in the same manner as a freestanding derivative. Accordingly, subsequent changes in the fair value of these redemption features are measured at each reporting period and recognized in the consolidated statement of operations and comprehensive loss. The sum of the fair value of the warrants, the fair value of the embedded redemption derivative liability, issuance costs, BCF and commission payments for the Convertible Notes were recorded as debt discounts to be amortized to interest expense over the respective term using the effective interest method. During the year ended December 31, 2021, the Company recognized interest expense of $0.8 million from the accretion of those debt discounts, respectively. The Convertible Notes automatically converted upon the closing of the IPO at the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to the closing of the IPO. The outstanding principal ($12.5 million) and interest due ($0.4 million) under the Convertible Notes, in an aggregate amount of $12.9 million, was converted into 5,015,494 shares of the Company’s common stock at the implied per share conversion of $2.5736. The carrying value of the Convertible Notes was credited to common stock and additional paid-in capital on the consolidated balance sheet. The remaining unamortized discount of $0.4 million was recorded to additional paid-in capital and no gain or loss was recognized on the conversion. The remaining unamortized discount related to the BCF of $0.5 million was recognized immediately as interest expense in the consolidated statement of operations and comprehensive loss. Derivative Liability As described above, the redemption provisions embedded in the Convertible Notes required bifurcation and measurement at fair value as a derivative. The fair value of the Convertible Note embedded redemption derivative liability was calculated by determining the value of the debt component of the Convertible Notes at various conversion or maturity dates using a Probability Weighted Expected Return valuation method. The fair value calculation placed greater probability on the occurrence of the conversion or the maturity date scenario, with little or no weight given to other scenarios. The fair value of the embedded redemption derivative liability is significantly influenced by the discount rate, the remaining term to maturity and the Company’s assumptions related to the probability of a qualified financing or no financing prior to maturity. The Financing Date is the estimated date of an automatic conversion as the result of a Next Qualified Equity Financing or an IPO. The embedded redemption derivative liability no longer had significant value as of the date of the Company’s IPO since the conversion of the Convertible Notes occurred via a redemption feature that was not bifurcated as a derivative. Upon the conversion of the Convertible Notes at the IPO, the Company recorded a final change in the fair value of the derivative liability of $0.1 million in the consolidated statement of operations and comprehensive loss, and the derivative liability was extinguished. The changes in the fair value of the derivative liability for the year ended December 31, 2021 is presented as follows (in thousands): Warrant Issuance December 31, Fair Value at Change in December 31, Derivative liability $ 121 — (121 ) $ —

Redeemable Convertible Preferre

Redeemable Convertible Preferred Stock	12 Months Ended
Redeemable Convertible Preferred Stock	Dec. 31, 2022
Redeemable Convertible Preferred Stock [Abstract]
REDEEMABLE CONVERTIBLE PREFERRED STOCK	Note 9 – REDEEMABLE Convertible Preferred Stock The Series B preferred stock was measured and recorded at the transaction price net of issuance costs, resulting in an initial value of $9.3 million. The accretion to the carrying value of the Series B preferred stock was recorded as a charge to additional paid in capital. The accumulated accretion as of the IPO date was $11.5 million, which resulted in an adjusted Series B preferred stock carrying value of $20.8 million. The accretion to the carrying value of the Series A preferred stock was recorded as a charge to additional paid-in capital. The accumulated accretion as of the IPO date was $8.2 million, which resulted in an adjusted Series A preferred stock carrying value of $14.5 million. Upon the IPO, the redeemable convertible preferred stock converted in to 11,436,956 shares of common stock and no shares of redeemable convertible preferred stock remain outstanding as of December 31, 2021. On March 24, 2021, the Company’s Third Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share. The significant rights and preferences of the preferred stock will be established by the Company’s Board of Directors (the “Board”) upon issuance of any such series of preferred stock in the future.

Common Stock

Common Stock	12 Months Ended
Common Stock	Dec. 31, 2022
Common Stock [Abstract]
COMMON STOCK	Note 10 – Common Stock As of December 31, 2022 and 2021, the Company was authorized to issue 75,000,000 shares of common stock with a par value of $0.0001 per share, and 33,659,460 and 32,772,060 shares were issued and outstanding, respectively. Conversion of Redeemable Convertible Preferred Stock In connection with the closing of the IPO, on March 25, 2021, the outstanding shares of the Company’s Series A and Series B redeemable convertible preferred stock were converted into 11,436,956 shares of the Company’s common stock. Conversion of Convertible Notes In connection with the funding of the IPO, on March 25, 2021, the principal and interest due under the Company’s Convertible Notes, in an aggregate amount of $12.9 million, was converted into 5,015,494 shares of the Company’s common stock. Third Amended and Restated Certificate of Incorporation In connection with the IPO, the Third Amended and Restated Certificate of Incorporation became effective and authorized 75,000,000 shares of common stock at par value of $0.0001 per share. Dividends may be declared and paid on the common stock when and if determined by the Board of Directors. Upon liquidation, each common stockholder is entitled to receive an equal portion of the distribution. Each holder of common stock will have one vote in respect of each share of common stock held. The rights and privileges listed above will be subject to preferential rights of any then outstanding shares of preferred stock. At the IPO date, the Company issued 17,000 shares of common stock for nonemployee services valued at $85,000. At-the-Market Issuance of Common Stock On August 15, 2022, the Company entered into an At-the-Market Issuance Agreement (the “Issuance Agreement”) with B. Riley Securities, Inc. (the “Sales Agent”). Pursuant to the terms of the Issuance Agreement, the Company may sell from time to time through the Sales Agent shares of the Company’s common stock having an aggregate offering price of up to $50,000,000 (the “Shares”). Sales of Shares, if any, may be made by means of transactions that are deemed to be “at the market” offerings as defined in Rule 415 under the Securities Act, including block trades, ordinary brokers’ transactions on the Nasdaq Capital Market or otherwise at market prices prevailing at the time of sale, at prices related to prevailing market prices or at negotiated prices or by any other method permitted by law. Under the terms of the Issuance Agreement, the Company may also sell Shares to the Sales Agent as principal for its own accounts at a price to be agreed upon at the time of sale. Any sale of Shares to the Sales Agent as principal would be pursuant to the terms of a separate terms agreement between the Company and the Sales Agent. The Company has no obligation to sell any of the Shares under the Issuance Agreement and may at any time suspend solicitation and offers under the Issuance Agreement. During the year ended December 31, 2022, the Company issued and sold an aggregate of 810,400 shares of common stock through the Issuance Agreement at a weighted-average public offering price of $2.84 per share and received net proceeds of $2.2 million. As of December 31, 2022, an aggregate offering price amount of approximately $47.7 million remains available to be issued and sold under the Issuance Agreement. Common Stock Reserved for Future Issuance Common stock reserved for future issuance at December 31, 2022 is summarized as follows: December 31, Warrants to purchase common stock 1,938,143 Stock options outstanding 6,919,894 Stock options available for future grants 6,711,065 Total 15,569,102 Restricted Stock Purchase Agreements In 2018, 400,000 shares of common stock were issued to the Company’s founder at inception pursuant to a Restricted Stock Purchase Agreement. The Restricted Stock Purchase Agreement stipulates that in the event of the voluntary or involuntary termination of the Company’s founder’s continuous service status for any reason (including death or disability), with or without cause, the Company or its assignees(s) shall have an option (“Repurchase Option”) to repurchase all or any portion of the shares held by the Purchaser as of the termination date which have not yet been released from the Company’s Repurchase Option at the original purchase price of $0.0125 per share. Shares are to be released from the Repurchase Option over four years. The initial 12/48ths of the shares were released on January 30, 2019, and an additional 1/48th of the shares are being released monthly thereafter. As of December 31, 2022 and 2021, no and 8,333 of the shares issued to the Company’s founder remain subject to the Repurchase Option, respectively. These shares were originally purchased by the Company’s founder at $0.0125 per share. In 2018, 3,640,000 shares of common stock were also issued pursuant to a Restricted Stock Purchase Agreement. The holders of these shares are considered related parties of the Company because the holders are directly related either to the founder or to the former legal counsel of the Company. The same terms described above apply to these issuances. As of December 31, 2022 and 2021, no and 75,833 of the shares issued to these holders remain subject to the Repurchase Option, respectively. These shares were originally purchased by the holders at $0.0125 per share. Early Exercised Stock Option Liability The Exercise Notice (Early Exercise) Agreement states that the Company has the option to repurchase all or a portion of the unvested shares in the event of the separation of the holder from service to the Company. The shares continue to vest in accordance with the original vesting schedules of the former option agreements. During the years ended December 31, 2022 and 2021, no and 50,000 shares of common stock were issued upon the early exercise of common stock options. As of December 31, 2022 and 2021, the Company has recorded a repurchase liability for approximately $136,000 and $281,000 for 266,147 and 567,397 shares that remain unvested, respectively. The weighted average remaining vesting period at December 31, 2022 is approximately 1.09 years.

Common Stock Warrants

Common Stock Warrants	12 Months Ended
Common Stock Warrants	Dec. 31, 2022
Common Stock Warrants [Abstract]
COMMON STOCK WARRANTS	Note 11 – Common Stock Warrants Preferred A Placement Warrants On February 22, 2018, the Company entered into an agreement with NSC, pursuant to which the Company engaged NSC as the Company’s exclusive financial advisor and placement agent in connection with an offering or series of offerings of Company securities. Specifically, NSC was the placement agent in connection with the sale of its Series A preferred stock. In connection with the closing of the Series A preferred stock offering, the Company issued warrants (“Preferred A Placement Warrants”) to purchase a total of 133,648 shares of its common stock to NSC on March 14, 2018 and April 23, 2018. The Preferred A Placement Warrants included an adjustment provision pursuant to which upon completion of the IPO, and the conversion of the Series A preferred stock in connection therewith, the number of shares issuable upon exercise of the warrants was adjusted to be equal to 10% of the aggregate number of common stock shares issued by the Company upon conversion of 1,336,485 shares of Series A preferred stock (the “Preferred A Adjustment Provision”). In August 2019, the Preferred A Placement Warrants were amended and reissued and the total number of warrant shares increased to 242,847. The Second Amended and Restated Certificate of Incorporation that was approved on March 28, 2019 amended and fixed the conversion price of the Series A preferred stock at $1.40. As a result, on August 28, 2019, the Company elected to amend and reissue the Preferred A Placement Warrants, thereby reducing the exercise price to $1.40 and increasing the number of warrant shares by 109,200 to a total of 242,847 warrant shares. In connection with the IPO, pursuant to the Preferred A Adjustment Provision variable settlement provision, the number of shares of common stock subject to the Preferred A Placement Warrants settled, resulting in an additional 50,195 shares of common stock. Preferred A Lead Investor Warrants During February 2021, a total of 52,500 warrants for common stock were issued to advisors to the Company at a weighted average exercise price of $0.0125 per share. The resulting fair value of the warrants for common stock is not significant. Preferred B Placement Warrants On April 16, 2019, in connection with the Series B preferred stock offering, the Company issued warrants (“Preferred B Placement Warrants”) to purchase 414,270 shares of its common stock to NSC, Newbridge Securities Corporation, and five individuals at LVP. The Preferred B Placement Warrants have a term of five years and their exercise price is equal to $2.10, the conversion price of Series B preferred stock. The Preferred B Placement Warrants included an adjustment provision pursuant to which upon completion of the IPO, and the conversion of the Series B preferred stock in connection therewith, the number of shares issuable upon exercise of the warrants was adjusted to be equal to 10% of the aggregate number of common stock shares issued by the Company upon conversion of 4,142,270 shares of Series B preferred stock (the “Preferred B Adjustment Provision”). In connection with the IPO, pursuant to the Preferred B Adjustment Provision variable settlement provision, the number of shares of common stock subject to the Preferred B Placement Warrants settled, resulting in an additional 49,528 shares of common stock. Convertible Note Placement Warrants In connection with the Convertible Notes, the Company issued 10,000 and 204,050 warrants to purchase common stock, to a noteholder and its brokers, respectively. The warrants have a five-year life and were initially exercisable into common stock at $2.97 per share with the warrants ultimately being exercisable into common stock at the final Conversion Price of the Convertible Notes. When the Convertible Notes converted at the IPO date as described in Note 8, the exercise price of the warrants was adjusted to equal the Conversion Price, which is $2.57. During March 2021, 42,220 of these warrants to purchase common stock were cancelled. Underwriter Warrants In connection with the IPO, the Company issued the underwriter a warrant to purchase shares of common stock equal to 9.79% of the shares of common stock sold in the IPO or 956,973 shares. The warrant is exercisable at $6.00 per share and has a 5-year term. The following is a summary of the Company’s warrant activity for the years ended December 31, 2022 and 2021: Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 293,042 — — — — 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 52,500 — — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 463,798 — — — — 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 171,830 — — — — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 956,973 — — — — 956,973 March 2026 1,938,143 — — — — 1,938,143 Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — 50,195 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 — 52,500 — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — 49,528 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 214,050 — — (42,220 ) — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 — 956,973 — — — 956,973 March 2026 871,167 1,009,473 — (42,220 ) 99,723 1,938,143 Warrants Classified as Liabilities Preferred A Placement Warrants and Preferred B Placement Warrants The Preferred A Placement Warrants and Preferred B Placement Warrants were initially classified as a derivative liability because their variable terms did not qualify these as being indexed to the Company’s own common stock and were initially measured at fair value on a recurring basis. As a result of the conversion of the Preferred Stock into common stock in connection with the IPO, and the related impact of the Preferred A Adjustment Provision and the Preferred B Adjustment Provision, the number of warrant shares that are convertible is no longer variable. Accordingly, the Preferred A Placement Warrants and Preferred B Placement Warrants were determined to be indexed to the Company’s own common stock and will no longer be measured at fair value on a recurring basis. Thus, the Preferred A Placement Warrants and the Preferred B Placement Warrants were determined to be equity instruments, and the liability was recorded at fair value with the change in fair value recorded in the consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital at their estimated fair value at the IPO date. Convertible Notes Placement Warrants The Convertible Notes Placement Warrants were classified as a derivative liability because the exercise price was variable, thus these did not qualify as being indexed to the Company’s own common stock and were measured at fair value on a recurring basis. As a result of the conversion of the Convertible Notes into common stock in connection with the IPO, the exercise price is no longer variable. Accordingly, the Convertible Notes Placement Warrants were determined to be indexed to the Company’s own common stock and will no longer be measured at fair value on a recurring basis. Thus, the Convertible Notes Placement Warrants were determined to be equity instruments, and the liability was recorded at fair value with the change in fair value recorded in the consolidated statement of operations and comprehensive loss and reclassified to additional paid-in capital at their estimated fair value at the IPO date. Estimated Fair Value of Outstanding Warrants Classified as Liabilities The estimated fair value of outstanding warrants classified as liabilities is determined at each consolidated balance sheet date. Any decrease or increase in the estimated fair value of the warrant liability since the most recent consolidated balance sheet date is recorded in the consolidated statements of operations and comprehensive loss as a change in fair value of warrant liability. There were no warrants classified as liabilities outstanding as of December 31, 2022 and 2021. The changes in fair value of the outstanding warrants classified as liabilities for the year ended December 31, 2021 were as follows (in thousands): Warrant Issuance Warrant Fair value Fair value Change in Reclassified Warrant Preferred A Placement Warrants $ 518 $ — $ — $ 575 $ (1,093 ) $ — Preferred B Placement Warrants 708 — — 800 (1,508 ) — Convertible Notes Placement Warrants 323 — — 206 (529 ) — $ 1,549 $ — $ — $ 1,581 $ (3,130 ) $ — The fair values of the outstanding warrants accounted for as liabilities at the IPO date are calculated using the Black-Scholes option pricing model with the following assumptions: Black-Scholes Fair Value Assumptions at IPO Date Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants — % 59.21 % 0.14 % 2.0 years Preferred B Placement Warrants — % 58.51 % 0.30 % 3.0 years Convertible Note Placement Warrants — % 52.28 % 0.82 % 4.4 years Upon the conversion of the redeemable convertible preferred stock and the Convertible Notes into common stock at the IPO date, the estimated fair value of the outstanding warrants accounted for as liabilities of $3.1 million was reclassified to additional paid-in capital. Warrants Classified as Equity Certain warrants are classified as equity instruments since they do not meet the characteristics of a liability or a derivative and are recorded at fair value on the date of issuance using the Black-Scholes option pricing model with the following assumptions. The fair value as determined at the issuance date is recorded as an issuance cost of the related stock. Those warrants and the assumptions used to calculate the fair value at issuance are as follows for the warrants issued during the year ended December 31, 2021. There were no warrants issued during the year ended December 31, 2022. Black-Scholes Fair Value Assumptions Warrant Issuance Issuance Fair Dividend Expected Risk-Free Expected Underwriter Warrants March 2021 $ 2,349 — % 52.58 % 0.82 % 5.0 years

Stock-Based Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	Note 12 – Stock-based Compensation 2019 Equity Incentive Plan Effective as of November 18, 2019, the Company adopted the 2019 Omnibus Incentive Plan (“2019 Plan”) administered by the Board. The 2019 Plan provides for the issuance of incentive stock options, non-statutory stock options, and restricted stock awards, for the purchase of up to a total of 4,000,000 shares of the Company’s common stock to employees, directors, and consultants and replaces the previous plan. The Board or a committee of the Board has the authority to determine the amount, type, and terms of each award. The options granted under the 2019 Plan generally have a contractual term of ten years and a vesting term of four years with a one-year cliff. The exercise price for options granted under the 2019 Plan must generally be at least equal to 100% of the fair value of the Company’s common stock at the date of grant, as determined by the Board. The incentive stock options granted under the 2019 Plan to 10% or greater stockholders must have an exercise price at least equal to 110% of the fair value of the Company’s common stock at the date of grant, as determined by the Board, and have a contractual term of ten years. In connection with the closing of the IPO, effective as of March 25, 2021 the 2019 Plan was amended and restated as a result of which the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan was increased from 6,000,000 to 7,400,000. On April 15, 2022, the Board approved, subject to stockholder approval, an increase in the aggregate number of shares of common stock that may be issued pursuant to the 2019 Plan from 7,400,000 to 13,400,000. On June 21, 2022, the stockholders approved this increase. As of December 31, 2022, the Company had 5,424,815 shares available for future grant under the 2019 Plan. 2021 Employment Inducement Plan On September 15, 2021 the Company’s Board adopted the Movano, Inc. 2021 Inducement Award Plan (the “Inducement Plan”) without stockholder approval pursuant to Rule 5635(c)(4) of the Nasdaq Stock Market LLC listing rules (“Rule 5635(c)(4)”). In accordance with Rule 5635(c)(4), awards under the Inducement Plan may only be made to a newly hired employee who has not previously been a member of the Company’s Board, or an employee who is being rehired following a bona fide period of non-employment by the Company or a subsidiary, as a material inducement to the employee’s entering into employment with the Company or its subsidiary. An aggregate of 2,000,000 shares of the Company’s common stock have been reserved for issuance under the Inducement Plan. As of December 31, 2022, the Company had 1,286,250 shares available for future grant under the Inducement Plan. Stock Options Stock option activity for the years ended December 31, 2022 and 2021 was as follows (in thousands, except share, per share, and remaining life data): Number of Weighted Weighted Intrinsic Outstanding at December 31, 2020 3,188,011 $ 0.66 9.0 years $ 8,155 Granted 2,684,500 $ 4.05 Exercised (134,541 ) $ 0.56 Cancelled (145,833 ) $ 0.59 Outstanding at December 31, 2021 5,592,137 $ 2.29 8.6 years $ 9,912 Granted 2,525,000 $ 2.77 Exercised (77,000 ) $ 0.40 Cancelled (1,120,243 ) $ 3.15 Outstanding at December 31, 2022 6,919,894 $ 2.34 8.2 years $ 2,034 Exercisable as of December 31, 2022 3,762,779 $ 1.74 7.7 years $ 1,826 Vested and expected to vest as of December 31, 2022 6,769,694 $ 2.32 8.2 years $ 1,988 The weighted-average grant date fair value of options granted during the years ended December 31, 2022, and 2021 was $1.48 and $2.54 per share, respectively. During the years ended December 31, 2022 and 2021, 77,000 and 134,531 options were exercised for proceeds of $31,000 and $0.1 million, respectively. The fair value of the 1,707,794 and 839,380 options that vested during the years ended December 31, 2022 and 2021 was approximately $3.2 million and $0.7 million, respectively. On June 21, 2022, the Company granted an award of 100,000 options to the Company’s founder at an exercise price of $5.00 per share. The options will vest in full upon the shipment of 20,000 product units on or before June 30, 2023. If the shipments have not occurred by June 30, 2023, the options will be cancelled and forfeited. For year ended December 31, 2022, the Company has not recognized stock compensation expense of approximately $0.1 million related to this award as the successful achievement of the performance conditions is not yet probable. The Company estimated the fair value of stock options using the Black-Scholes option pricing model. The fair value of the stock options was estimated using the following weighted average assumptions for the years ended December 31, 2022 and 2021. Year Ended December 31, 2022 2021 Dividend yield — % — % Expected volatility 61.97 % 66.38 % Risk-free interest rate 2.78 % 0.93 % Expected life 6.07 years 6.05 years Dividend Rate Expected Volatility Risk-Free Interest Rate Expected Term Forfeiture Rate The Company has recorded stock-based compensation expense for the years ended December 31, 2022 and 2021 related to the issuance of stock option awards to employees and nonemployees in the consolidated statement of operations and comprehensive loss as follows: Year Ended December 31, 2022 2021 Research and development $ 1,169 $ 716 Sales, general and administrative 1,927 1,138 $ 3,096 $ 1,854 As of December 31, 2022, unamortized compensation expense related to unvested stock options was approximately $6.6 million, which is expected to be recognized over a weighted average period of 2.6 years.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	Note 13 – Commitments and Contingencies Operating Leases As of December 31, 2022, the Company had one office lease for the Corporate headquarters and laboratory space. On April 15, 2021, the Company executed a lease agreement for corporate office space. The lease commenced on May 14, 2021 when the improvements were completed by the landlord and the Company had access to the facility. The lease term is 40 months, and the base rent is approximately $14,000 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid a security deposit of approximately $47,000. On April 22, 2022, the Company executed an amendment to its corporate office lease agreement for additional corporate office space. The lease term for the additional space is 36 months from the expansion commencement date of June 23, 2022. The base rent is approximately $5,100 per month for the first twelve months, with subsequent escalation provisions for future months. The Company paid an additional security deposit of approximately $5,500. On January 1, 2022, the Company adopted ASC 842. Under this new guidance, lessees are required to recognize assets and liabilities on the balance sheet for the rights and obligations created by all leases. Upon adoption, the Company recognized ROU assets of $380,000 and corresponding lease liabilities of $429,000 for the one operating lease of the Company at the adoption date. The components of lease expense and supplemental cash flow information as of and for the year ended December 31, 2022 are as follows (in thousands): Operating leases As of Right-of-use assets $ 389 Operating lease liabilities - Short-term $ 212 Operating lease liabilities - Long-term $ 214 Year Ended December 31, Lease Cost: Operating lease cost $ 226 Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended $ 209 Weighted average remaining lease term - operating leases (in years) 1.97 Average discount rate - operating lease 10.00 % Future minimum lease payments for this new corporate office space lease are as follows as of December 31, 2022 (in thousands): 2023 $ 242 2024 203 2025 27 Total lease payments 472 Less: Interest (46 ) Total operating lease liability $ 426 Rent expense for the years ended December 31, 2022 and 2021 was $226,000 and $154,000, respectively. Litigation From time to time, the Company may become involved in various litigation and administrative proceedings relating to claims arising from its operations in the normal course of business. Management is not currently aware of any matters that may have a material adverse impact on the Company’s business, financial position, results of operations or cash flows. Indemnification The Company enters into standard indemnification agreements in the ordinary course of business. Pursuant to these arrangements, the Company indemnifies, holds harmless and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified party, in connection with any trade secret, copyright, patent or other intellectual property infringement claim by any third party with respect to its technology. The term of these indemnification agreements is generally perpetual after the execution of the agreement. The maximum potential amount of future payments the Company could be required to make under these agreements is not determinable because it involves claims that may be made against the Company in the future, but have not yet been made. The Company has not incurred costs to defend lawsuits or settle claims related to these indemnification agreements. The Company has entered into indemnification agreements with its directors and officers that may require the Company to indemnify its directors and officers against liabilities that may arise by reason of their status or service as directors or officers, other than liabilities arising from willful misconduct of the individual. No amounts associated with such indemnifications have been recorded as of December 31, 2022. Non-cancelable Obligations The Company also had $0.4 million of non-cancelable contractual commitments as of December 31, 2022, primarily related to its vendor arrangements. These commitments are generally due within one to ten months.

Income Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2022
Income Tax Disclosure [Abstract]
INCOME TAXES	NOTE 14 – INCOME TAXES For the years ended December 31, 2022 and 2021, no U.S. provision or benefit for income taxes was recorded and an insignificant amount of Ireland provision for income taxes for the year ended December 31, 2022 was offset by credits. The effective tax rate of the Company’s provision (benefit) for income taxes differs from the federal rate as follows: Year Ended 2022 2021 US federal provision (benefit) At statutory rate 21 % 21 % Valuation allowance (22 )% (18 )% Changes in stock-based compensation, fair value of warrants and derivative liability and interest expense for convertible promissory notes (1 )% (3 )% Other 1 % 1 % Effective tax rate — — Significant components of the Company’s deferred tax assets and liabilities as of December 31, 2022 and 2021 are as follows (in thousands): 2022 2021 Gross deferred tax assets: Net operating loss carryforwards $ 10,040 $ 7,765 Research and development credit carryforward 1,434 712 Capitalized research and development 3,444 — Accrued bonus 464 403 Stock-based compensation 590 72 Lease liabilities 90 — Other 53 76 Total gross deferred tax assets 16,115 9,029 Less valuation allowance (16,024 ) (9,022 ) Total net deferred tax assets 91 7 Deferred tax liabilities: Property and equipment (9 ) (7 ) Right-of-use assets (82 ) — Total deferred tax liabilities (91 ) (7 ) Net deferred tax assets $ — $ — During 2022 and 2021, the Company has maintained a valuation allowance against the net deferred tax assets due to the uncertainty surrounding the realization of those assets. The Company periodically evaluates the recoverability of the deferred tax assets and, when it is determined to be more-likely-than-not that the deferred tax assets are realizable, the valuation allowance is reduced. The valuation allowance increased by approximately $7,002,000 and $4,034,000 during the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022 and 2021, the Company has federal net operating loss carryforwards of approximately $48.5 million and $37.4 million, respectively, all of which do not expire. The net operating loss carryforwards may be available to offset future taxable income for income tax purposes. As of December 31, 2022 and 2021, the Company has federal research and development (“R&D”) credit carryforwards of approximately $1,179,000 and $565,000, respectively. The federal R&D credits begin to expire in 2039. As of December 31, 2022 and 2021, the Company has California R&D credit carryforwards of approximately $1,066,000 and $640,000, respectively. The California R&D credits do not expire. In accordance with the 2017 Tax Act, research and experimental, or R&E, expenses under IRC Section 174 are required to be capitalized beginning in 2022. R&E expenses are required to be amortized over a period of five years for domestic expenses and 15 years for foreign expenses. The Internal Revenue Code imposes limitations on a corporation’s ability to utilize net operating loss (“NOL”) and credit carryovers if it experiences an ownership change as defined in Section 382. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50% over a three-year period. If an ownership change has occurred, or were to occur, utilization of the Company’s NOLs and credit carryovers could be restricted. The Company accounts for uncertainty in income taxes pursuant to the relevant authoritative guidance. The guidance clarified the recognition of tax positions taken, or expected to be taken, on a tax return. The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant taxing authority. An uncertain tax position will not be recognized if it has a less than 50% likelihood of being sustained. No liability related to uncertain tax positions is recorded in the financial statements. The Company files income tax returns in the U.S. federal jurisdiction and in California. For jurisdictions in which tax filings have been filed, all tax years remain open for examination by the federal and California state authorities for three and four years, respectively, from the date of utilization of any net operating losses or credits. Total gross unrecognized tax benefit liabilities as of December 31, 2022 and 2021 were approximately $811,000 and $487,000, respectively, related to Federal and California R&D credits. As of December 31, 2022 and 2021, the Company had no unrecognized tax benefits, which, if recognized would affect the Company’s effective tax rate due to the full valuation allowance. The Company’s policy is to classify interest and penalties related to unrecognized tax benefits as part of the income tax provision (benefit) in the statements of operations and comprehensive loss. The Company had no accrued interest and penalties related to unrecognized tax benefits as of December 31, 2022. The following is a rollforward of the total gross unrecognized tax benefits for the years ended December 31, 2022 and 2021 (in thousands): Year Ended December 31, 2022 2021 Beginning Balance $ 487 $ 289 Gross Increases - Tax Position in Prior Periods 1 — Gross Increases - Tax Position in Current Period 323 198 Ending Balance $ 811 $ 487 All tax years remain subject to examination by the U.S. federal and state taxing authorities due to the Company’s net operating losses and R&D credit carry carryforwards.

Net Loss Per Share Attributable

Net Loss Per Share Attributable to Common Stockholders	12 Months Ended
Net Loss Per Share Attributable to Common Stockholders	Dec. 31, 2022
Earnings Per Share [Abstract]
NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS	Note 15 – NET LOSS PER SHARE ATTRIBUTABLE TO COMMON STOCKHOLDERS The following table computes the computation of the basic and diluted net loss per share attributable to common stockholders during the years ended December 31, 2022 and 2021 is as follows (in thousands, except share and per share data): Year Ended December 31, 2022 2021 Numerator: Net loss $ (30,329 ) $ (21,773 ) Accretion and dividends on redeemable convertible preferred stock — (2,489 ) Net loss attributable to common stockholders $ (30,329 ) $ (24,262 ) Denominator: Weighted-average common shares outstanding 33,025,721 26,298,032 Net loss per share attributable to common stockholders, basic and diluted $ (0.92 ) $ (0.92 ) The potential shares of common stock that were excluded from the computation of diluted net loss per share attributable to common stockholders for the years ended December 31, 2022 and 2021 because including them would have been antidilutive are as follows: Year Ended December 31, 2022 2021 Non-vested shares under restricted stock grants - 84,167 Shares subject to options to purchase common stock 6,769,694 5,541,937 Shares subject to warrants to purchase common stock 1,938,143 1,938,143 Total 8,707,837 7,564,247 For the years ended December 31, 2022 and 2021, performance based option awards for 150,200 and 50,200 shares of common stock, respectively, are not included in in the table above or considered in the calculation of diluted earnings per share until the performance conditions of the option award are considered probable by the Company.

Subsequent Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2022
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 16 – Subsequent Events On February 6, 2023, the Company completed a $7.5 million underwritten public offering of 5,340,600 shares of its common stock and warrants to purchase up to 2,670,300 shares of common stock, including the full exercise of the underwriter's overallotment option. The warrants were offered at the rate of one warrant for every two shares of purchased common stock and are exercisable at a price per share of $1.57 and expire five years after the date of issuance. Beginning on the one-year anniversary of the close of the offering, all outstanding warrants may be redeemed at the option of the Company, in whole or in part on a pro-rata basis, at the redemption price of $0.025 per warrant, provided that (i) the closing price of the Company’s common stock has equaled or exceeded $4.87 per share for ten consecutive trading days and (ii) the daily trading volume of the common stock on the Company’s primary trading market exceeded 100,000 shares on each of such ten trading days. The public offering price per share, before the underwriters' discount and commissions, for each share of common stock and accompanying warrant was $1.40. All of the securities in the underwritten public offering were sold by the Company. The warrants will not be listed on any securities exchange or other nationally recognized trading system. The net proceeds from the offering were approximately $6.85 million. During February 2023, the Company granted common stock option awards to non-executive employees, covering a total of 60,000 shares of common stock, at an exercise price of $1.37 per share. During February 2023, the Board approved the amendment of 293,042 Preferred A Placement Warrants to extend the maturity date by six months for each warrant and to remove the cashless exercise provision in the warrant agreements. The amended maturity dates for 234,197 and 58,845 Preferred A Placement Warrants will be in September 2023 and October 2023, respectively. During January and February 2023, the Company issued common stock upon the exercise of 245,855 common stock option awards at a weighted average exercise price of $0.44 and proceeds of $0.1 million. During March 2023, the Company granted common stock option awards to executive employees, covering a total of 562,875 shares of common stock and to non-executive employees for a total of 662,500 shares of common stock. The exercise price is $1.29 per share. During March 2023, the Company sold 2,070,616 shares of common stock under the ATM equity offering program at a weighted average price of $1.36 per share for gross proceeds of approximately $2.8 million. During March 2023, the Preferred A Lead Investor Warrants for 52,500 shares of common stock expired.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Dec. 31, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company has prepared the accompanying consolidated financial statements in accordance with GAAP.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting periods. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the accrual of research and development expenses, the valuation of common stock, stock options and warrants, the valuation of the embedded redemption derivative liability and income taxes. Estimates are periodically reviewed considering changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known. Actual results could differ from those estimates or assumptions.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business in one segment. The Company’s chief operating decision maker is the Chief Executive Officer.
Cash, Cash Equivalents and Short-term Investments	Cash, Cash Equivalents and Short-term Investments The Company invests its excess cash primarily in money market funds, commercial paper and short-term debt securities. The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. The Company classifies all marketable securities for use in current operations, even if the security matures beyond 12 months, and presents them as short-term investments in the consolidated balance sheets. The Company determines the appropriate classification of marketable securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for the purchased marketable securities as available-for-sale. After considering the Company’s capital preservation objectives, as well as its liquidity requirements, the Company may sell securities prior to their stated maturities. The Company carries its available-for-sale short-term investments at fair value. The Company reports the unrealized gains and losses, net of taxes, as a component of stockholders’ equity, except for unrealized losses determined to be credit-related, which are recorded as other income (expense), net in the consolidated statements of operations and comprehensive loss and reports an allowance for credit losses in short-term investments on the balance sheet, if any. The Company determines any realized gains or losses on the sale of short-term investments on a specific identification method and records such gains and losses as a component of other income (expense), net. Interest earned on cash, cash equivalents, and short-term investments is recorded in interest and other income, net in the accompanying consolidated statements of operations and comprehensive loss and was $277,000 and insignificant during the years ended December 31, 2022 and 2021. The Company’s investment policy only allows purchases of high credit quality instruments and provides guidelines on concentrations and credit quality to ensure minimum risk of loss. The Company evaluates whether the unrealized loss on available-for-sale short-term investments is the result of the credit worthiness of the securities it held, or other non-credit-related factors such as liquidity by reviewing a number of factors such as the implied yield of the corporate note based on the market price, the nature of the invested entity’s business or industry, market capitalization relative to debt, changes in credit ratings, and the market prices of the instruments subsequent to the period end.
Concentrations of Credit Risk and Off-Balance Sheet Risk	Concentrations of Credit Risk and Off-Balance Sheet Risk Cash and cash equivalents are financial instruments that are potentially subject to concentrations of credit risk. All cash and cash equivalents are held in United States financial institutions. Cash equivalents consist of interest-bearing money market accounts and institutional money market funds. The amounts deposited in the money market accounts exceed federally insured limits. Further, the Company has amounts in excess of federally insured limits as of December 31, 2022 at one financial institution that totaled approximately $2.3 million. The Company has not experienced any losses related to this account and believes the associated credit risk to be minimal due to the financial condition of the depository institutions in which those deposits are held. The Company is dependent on third-party manufacturers to supply products for research and development activities. These programs could be adversely affected by a significant interruption in the supply of such materials. The Company has no financial instruments with off-balance sheet risk of loss.
Prepaid Expenses and Other Current Assets	Prepaid Expenses and Other Current Assets Prepaid expenses and other current assets were comprised of prepaid expenses, other current receivables, and deferred offering costs, which consist of legal, accounting, filing and other fees related to the IPO that were capitalized prior to the IPO. The deferred offering costs were offset against proceeds from the IPO within additional paid-in capital upon the effective date of the IPO.
Software Development Costs	Software Development Costs Costs related to software development are included in research and development expense until the point that technological feasibility is reached, which, for the Company’s product, will be shortly before the product is released to manufacturing. Once technological feasibility is reached, such costs are capitalized and amortized to cost of revenue over the estimated lives of the product. During the years ended December 31, 2022 and 2021, no development costs were capitalized.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company reviews the impairment of long-lived assets whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated future cash flows expected to result from the use of the asset and its eventual disposition is less than its carrying amount.
Paycheck Protection Program Loan	Paycheck Protection Program Loan The Company accounted for funds received from the Paycheck Protection Program as a financial liability with interest accrued and expensed over the term of the loan under the effective interest method. The loan remained recorded as a liability until the Company was legally released from the liability. The amount that was ultimately forgiven by the lender was recognized in the consolidated statement of operations and comprehensive loss as a gain on extinguishment.
Convertible Financial Instruments	Convertible Financial Instruments The Company bifurcates embedded redemption and conversion options from their host instruments and accounts for them as freestanding derivative financial instruments at fair value if certain criteria are met. The criteria include circumstances in which (a) the economic characteristics and risks of the embedded derivative instrument are not clearly and closely related to the economic characteristics and risks of the host contract, (b) the hybrid instrument that embodies both the embedded derivative instrument and the host contract is not re-measured at fair value under otherwise applicable GAAP with changes in fair value reported in earnings as they occur and (c) a separate instrument with the same terms as the embedded derivative instrument would be considered a derivative instrument. Debt discounts under these arrangements are amortized to interest expense using the interest method over the earlier of the term of the related debt or their earliest date of redemption. From time to time, the Company issues convertible financial instruments to nonemployees in payment for services that are provided. Until the services are completely rendered, the Company will expense the principal and any interest earned prior to the service completion to the representative expense account for the services performed and will record a noncurrent liability for the expected amount of the principal balance. Upon completion of the services, the Company will reclassify the noncurrent liability balance to the balance of an outstanding convertible financial instrument and assess the embedded redemption and conversion options that are applicable at that time.
Beneficial Conversion Feature	Beneficial Conversion Feature If the conversion feature of conventional convertible promissory notes provides for a rate of conversion that is below fair value, this feature is characterized as a beneficial conversion feature (“BCF”). A BCF is recorded by the Company as a debt discount and as additional paid-in capital on the consolidated balance sheet. In those circumstances, the convertible debt is recorded net of the discount related to the BCF and the Company amortizes the discount to interest expense over the life of the debt using the effective interest method.
Redeemable Convertible Preferred Stock	Redeemable Convertible Preferred Stock The Company records all shares of redeemable convertible preferred stock at their respective issuance price less issuance costs on the dates of issuance. Under certain circumstances the Company would have been required to redeem the Series A and Series B redeemable convertible preferred stock unless an IPO had been consummated prior to April 1, 2021, or an extension or waiver was obtained upon approval of a majority of the holders of such preferred stock. As the preferred stock became redeemable due to the passage of time, the Company considered the preferred stock to be redeemable as of April 1, 2021. The Company recorded the accretion of the Series A and B preferred stock balances to their respective redemption amounts using the effective interest method. The redeemable convertible preferred stock is presented outside of stockholders’ deficit on the consolidated balance sheet as of December 31, 2020. Upon the IPO, the redeemable convertible preferred stock converted into 11,436,956 shares of common stock.
Comprehensive Loss	Comprehensive Loss Comprehensive loss is the change in stockholders’ equity (deficit) from transactions and other events and circumstances other than those resulting from investments by stockholders and distributions to stockholders. The Company’s other comprehensive loss is comprised of unrealized gains and losses on investments in available-for-sale securities.
Research and Development	Research and Development Research and development costs are expensed as incurred and consist of salaries and benefits, stock-based compensation expense, lab supplies and facility costs, as well as fees paid to other nonemployees and entities that conduct certain research and development activities on the Company’s behalf.
Stock-Based Compensation	Stock-Based Compensation The Company measures equity classified stock-based awards granted to employees, directors, and nonemployees based on the estimated fair value on the date of grant and recognizes compensation expense of those awards on a straight-line basis over the requisite service period, which is generally the vesting period of the respective award. The fair value of each stock option grant is estimated on the date of grant using the Black-Scholes option pricing model. This valuation model for stock-based compensation expense requires the Company to make assumptions and judgments about the variables used in the calculation including the expected term, the volatility of the Company’s common stock, and an assumed risk-free interest rate. The Company accounts for forfeitures as they occur.
Early Exercised Stock Option Liability	Early Exercised Stock Option Liability Upon the early exercise of stock options by employees, the Company records as a liability the purchase price of unvested common stock that the Company has a right to repurchase if and when the employment of the stockholder terminates before the end of the requisite service period. The proceeds originally recorded as a liability are reclassified to additional paid-in capital as the Company’s repurchase right lapses.
Income Taxes	Income Taxes The Company accounts for income taxes using the asset and liability method. Under this method, deferred tax assets and liabilities are determined based on differences between the financial statement and tax basis of assets and liabilities and net operating loss and credit carryforwards using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. As the Company maintained a full valuation allowance against its deferred tax assets, the changes resulted in no provision or benefit from income taxes during the year ended December 31, 2022 and 2021. The Company accounts for unrecognized tax benefits using a more-likely-than-not threshold for financial statement recognition and measurement of tax positions taken or expected to be taken in a tax return. The Company establishes a liability for tax-related uncertainties based on estimates of whether, and the extent to which, additional taxes will be due. The Company records an income tax liability, if any, for the difference between the benefit recognized and measured and the tax position taken or expected to be taken on the Company’s tax returns. To the extent that the assessment of such tax positions changes, the change in estimate is recorded in the period in which the determination is made. The liability is adjusted considering changing facts and circumstances, such as the outcome of a tax audit. The provision for income taxes includes the impact of liability provisions and changes to the liability that are considered appropriate. Changes in recognition or measurement are reflected in the period in which the change in judgment occurs.
Net Loss per Share Attributable to Common Stockholders	Net Loss per Share Attributable to Common Stockholders Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. The net loss attributable to common stockholders is calculated by adjusting the net loss of the Company for the accretion on the Series A and B redeemable convertible preferred stock and cumulative dividends on Series A and B redeemable convertible preferred stock. Diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders, since the effects of potentially dilutive securities are antidilutive.
Recently Adopted Accounting Pronouncements	Recently Adopted Accounting Pronouncements The Company adopted FASB’s ASU No. 2016-02, Leases In addition, the Company elected the package of practical expedients and other expedients permitted under the transition guidance within the new standard, which among other things, allowed the Company to carry forward the historical lease classification and not to restate the comparative periods prior to the adoption and to combine lease and non-lease components for all asset classes. The Company made an accounting policy election not to recognize right of use assets and lease liabilities for leases with a lease term of 12 months or less, including renewal options that are reasonably certain to be exercised, that also do not include an option to purchase the underlying asset that is reasonably certain of exercise. Instead, lease payments for these leases are recognized as lease expense on a straight-line basis over the lease term. The disclosures required under ASC 842 are not presented for periods before the date of adoption. For the comparative periods prior to adoption, the Company presented the disclosures which were required under the previous accounting guidance. The adoption of the new standard did not have a material impact on the Company’s results of operations or cash flows. Operating lease right of use (“ROU”) assets represent the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. Adoption of the new standard resulted in the recording of operating lease liabilities of $429,000 and ROU assets of $380,000 as of January 1, 2022. The difference between the ROU assets and lease liabilities represents the net book value of deferred rent recognized as of December 31, 2021, which was adjusted against the ROU asset upon adoption. The ROU asset is included in other assets on the Company’s consolidated balance sheet. At adoption, operating lease liabilities of $166,000 and $263,000, respectively, were included in other current liabilities and other noncurrent liabilities on the Company’s consolidated balance sheet. As most leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in research and development expenses and sales, general and administrative expenses in the consolidated statements of operations and comprehensive loss. Variable lease payments for common area maintenance, property taxes and other operating expenses are recognized as expense in the period when the changes in facts and circumstances on which the variable lease payments are based occur.

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2022
Fair Value Measurements [Abstract]
Schedule of assets and liabilities that are measured at fair value	December 31, 2022 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 8,171 $ 8,171 $ — $ — Total cash equivalents $ 8,171 $ 8,171 $ — $ — December 31, 2021 Fair Value Level 1 Level 2 Level 3 Cash equivalents: Money market funds $ 16,830 $ 16,830 $ — $ — Total cash equivalents $ 16,830 $ 16,830 $ — $ — Short-term investments: Certificates of deposit $ 250 $ — $ 250 $ — Commercial paper 2,210 — 2,210 — Corporate notes 12,024 — 12,024 — Municipal bonds 1,437 — 1,437 — Total short-term investments $ 15,921 $ — $ 15,921 $ —

Cash, Cash Equivalents and Sh_2

Cash, Cash Equivalents and Short-Term Investments (Tables)	12 Months Ended
Cash, Cash Equivalents and Short-Term Investments (Tables)	Dec. 31, 2022
Cash and Cash Equivalents [Abstract]
Schedule of cash, cash equivalents and short-term investments	December 31, 2022 2021 Cash and cash equivalents: Cash $ 2,588 $ 845 Money market funds 8,171 16,830 Total cash and cash equivalents $ 10,759 $ 17,675 Short-term investments: Certificates of deposit $ — $ 250 Commercial paper — 2,210 Corporate notes — 12,024 Municipal bonds — 1,437 Total short-term investments $ — $ 15,921
Schedule of short-term investments	December 31, 2021 Amortized Gross Gross Aggregate Short-term investments: Certificates of deposit $ 250 $ — $ — $ 250 Commercial paper 2,210 — — 2,210 Corporate notes 12,035 — (11 ) 12,024 Municipal bonds 1,437 — — 1,437 Total short-term investments $ 15,932 $ — $ (11 ) $ 15,921

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2022
Property and Equipment [Abstract]
Schedule of property and equipment	December 31, 2022 2021 Office equipment and furniture $ 263 $ 237 Software 131 115 Test equipment 277 278 Total property and equipment 671 630 Less: accumulated depreciation (228 ) (101 ) Total property and equipment, net $ 443 $ 529

Other Current Liabilities (Tabl

Other Current Liabilities (Tables)	12 Months Ended
Other Current Liabilities (Tables)	Dec. 31, 2022
Other Current Liabilities [Abstract]
Schedule of other current liabilities	December 31, 2022 2021 Accrued compensation $ 2,708 $ 2,211 Accrued severance payment 517 — Accrued research and development 536 289 Accrued vacation 243 276 Lease liabilities, current portion 212 — Other 205 131 Total other current liabilities $ 4,421 $ 2,907

Convertible Promissory Notes (T

Convertible Promissory Notes (Tables)	12 Months Ended
Convertible Promissory Notes (Tables)	Dec. 31, 2022
Convertible Promissory Notes [Abstract]
Schedule of convertible notes	Conversion Event Description Conversion Price Automatic Conversion – Next Qualified Equity Financing Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Qualified Equity Financing closing. Automatic Conversion – Change of Control (defined as consolidation or merger of the Company or transfer of a majority of share ownership or disposition of substantially all assets of the Company) If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control. Automatic Conversion – Maturity Date If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect. An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date. Automatic Conversion – IPO If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price. An amount equal to the lower of (i) 80% of the lowest per-share selling price of the Common Stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO. Conversion Event Description Conversion Price Optional Conversion If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect. An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing.
Schedule of fair value of the derivative liability	Warrant Issuance December 31, Fair Value at Change in December 31, Derivative liability $ 121 — (121 ) $ —

Common Stock (Tables)

Common Stock (Tables)	12 Months Ended
Common Stock (Tables)	Dec. 31, 2022
Common Stock [Abstract]
Schedule of common stock reserved for future issuance	December 31, Warrants to purchase common stock 1,938,143 Stock options outstanding 6,919,894 Stock options available for future grants 6,711,065 Total 15,569,102

Common Stock Warrants (Tables)

Common Stock Warrants (Tables)	12 Months Ended
Common Stock Warrants (Tables)	Dec. 31, 2022
Common Stock Warrants [Abstract]
Schedule of company's warrant activity	Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 293,042 — — — — 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 52,500 — — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 463,798 — — — — 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 171,830 — — — — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 956,973 — — — — 956,973 March 2026 1,938,143 — — — — 1,938,143 Warrant Issuance Issuance Exercise Outstanding, Granted Exercised Canceled/ Variable Outstanding, Expiration Preferred A Placement Warrants March and April 2018 and August 2019 $ 1.40 242,847 — — — 50,195 293,042 March and April 2023 Preferred A Lead Investor Warrants February 2021 $ 0.0125 — 52,500 — — — 52,500 March 2023 Preferred B Placement Warrants April 2019 $ 2.10 414,270 — — — 49,528 463,798 April 2024 Convertible Notes Placement Warrants August 2020 $ 2.57 214,050 — — (42,220 ) — 171,830 August 2025 Underwriter Warrants March 2021 $ 6.00 — 956,973 — — — 956,973 March 2026 871,167 1,009,473 — (42,220 ) 99,723 1,938,143
Schedule of changes in fair value of the outstanding warrants	Warrant Issuance Warrant Fair value Fair value Change in Reclassified Warrant Preferred A Placement Warrants $ 518 $ — $ — $ 575 $ (1,093 ) $ — Preferred B Placement Warrants 708 — — 800 (1,508 ) — Convertible Notes Placement Warrants 323 — — 206 (529 ) — $ 1,549 $ — $ — $ 1,581 $ (3,130 ) $ —
Schedule of black-scholes option pricing model assumptions	Black-Scholes Fair Value Assumptions at IPO Date Warrant Issuance Dividend Expected Risk-Free Expected Preferred A Placement Warrants — % 59.21 % 0.14 % 2.0 years Preferred B Placement Warrants — % 58.51 % 0.30 % 3.0 years Convertible Note Placement Warrants — % 52.28 % 0.82 % 4.4 years
Schedule of fair value at issuance for warrants	Black-Scholes Fair Value Assumptions Warrant Issuance Issuance Fair Dividend Expected Risk-Free Expected Underwriter Warrants March 2021 $ 2,349 — % 52.58 % 0.82 % 5.0 years

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2022
Share-Based Payment Arrangement [Abstract]
Schedule of stock option activity	Number of Weighted Weighted Intrinsic Outstanding at December 31, 2020 3,188,011 $ 0.66 9.0 years $ 8,155 Granted 2,684,500 $ 4.05 Exercised (134,541 ) $ 0.56 Cancelled (145,833 ) $ 0.59 Outstanding at December 31, 2021 5,592,137 $ 2.29 8.6 years $ 9,912 Granted 2,525,000 $ 2.77 Exercised (77,000 ) $ 0.40 Cancelled (1,120,243 ) $ 3.15 Outstanding at December 31, 2022 6,919,894 $ 2.34 8.2 years $ 2,034 Exercisable as of December 31, 2022 3,762,779 $ 1.74 7.7 years $ 1,826 Vested and expected to vest as of December 31, 2022 6,769,694 $ 2.32 8.2 years $ 1,988
Schedule of weighted average assumptions for fair value of options estimated	Year Ended December 31, 2022 2021 Dividend yield — % — % Expected volatility 61.97 % 66.38 % Risk-free interest rate 2.78 % 0.93 % Expected life 6.07 years 6.05 years
Schedule of stock-based compensation expense to employees and non-employees	Year Ended December 31, 2022 2021 Research and development $ 1,169 $ 716 Sales, general and administrative 1,927 1,138 $ 3,096 $ 1,854

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2022
Commitments and Contingencies Disclosure [Abstract]
Schedule of components of lease expense and supplemental cash flow information	Operating leases As of Right-of-use assets $ 389 Operating lease liabilities - Short-term $ 212 Operating lease liabilities - Long-term $ 214 Year Ended December 31, Lease Cost: Operating lease cost $ 226 Other Information: Cash paid for amounts included in the measurement of lease liabilities for the year ended $ 209 Weighted average remaining lease term - operating leases (in years) 1.97 Average discount rate - operating lease 10.00 %
Schedule of future minimum lease payments	2023 $ 242 2024 203 2025 27 Total lease payments 472 Less: Interest (46 ) Total operating lease liability $ 426

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2022
Income Tax Disclosure [Abstract]
Schedule of the effective tax rate of the company’s provision (benefit) for income taxes differs from the federal rate	Year Ended 2022 2021 US federal provision (benefit) At statutory rate 21 % 21 % Valuation allowance (22 )% (18 )% Changes in stock-based compensation, fair value of warrants and derivative liability and interest expense for convertible promissory notes (1 )% (3 )% Other 1 % 1 % Effective tax rate — —
Schedule of significant components of the company’s deferred tax assets and liabilities	2022 2021 Gross deferred tax assets: Net operating loss carryforwards $ 10,040 $ 7,765 Research and development credit carryforward 1,434 712 Capitalized research and development 3,444 — Accrued bonus 464 403 Stock-based compensation 590 72 Lease liabilities 90 — Other 53 76 Total gross deferred tax assets 16,115 9,029 Less valuation allowance (16,024 ) (9,022 ) Total net deferred tax assets 91 7 Deferred tax liabilities: Property and equipment (9 ) (7 ) Right-of-use assets (82 ) — Total deferred tax liabilities (91 ) (7 ) Net deferred tax assets $ — $ —
Schedule of rollforward of the total gross unrecognized tax benefits	Year Ended December 31, 2022 2021 Beginning Balance $ 487 $ 289 Gross Increases - Tax Position in Prior Periods 1 — Gross Increases - Tax Position in Current Period 323 198 Ending Balance $ 811 $ 487

Net Loss Per Share Attributab_2

Net Loss Per Share Attributable to Common Stockholders (Tables)	12 Months Ended
	Dec. 31, 2022
Earnings Per Share [Abstract]
Schedule of basic and diluted net loss per share attributable to common stockholders	Year Ended December 31, 2022 2021 Numerator: Net loss $ (30,329 ) $ (21,773 ) Accretion and dividends on redeemable convertible preferred stock — (2,489 ) Net loss attributable to common stockholders $ (30,329 ) $ (24,262 ) Denominator: Weighted-average common shares outstanding 33,025,721 26,298,032 Net loss per share attributable to common stockholders, basic and diluted $ (0.92 ) $ (0.92 )
Schedule of diluted net loss per share attributable to common stockholders	Year Ended December 31, 2022 2021 Non-vested shares under restricted stock grants - 84,167 Shares subject to options to purchase common stock 6,769,694 5,541,937 Shares subject to warrants to purchase common stock 1,938,143 1,938,143 Total 8,707,837 7,564,247

Business Organization, Nature_2

Business Organization, Nature of Operations (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended			12 Months Ended
	Feb. 06, 2023	Feb. 28, 2023	Jan. 31, 2023	Mar. 25, 2021	Dec. 31, 2022
Business Organization, Nature of Operations (Details) [Line Items]
Net proceeds				$ 44,300
Underwriting discounts				3,300
Offering expenses				$ 1,300
Received proceeds					$ 2,200
Aggregate offering price					47,700
Accumulated deficit					$ 95,100
IPO [Member] \| Common Stock [Member]
Business Organization, Nature of Operations (Details) [Line Items]
Shares of common stock (in Shares)					9,775,000
Public price per share (in Shares)					5
Subsequent Event [Member]
Business Organization, Nature of Operations (Details) [Line Items]
Net proceeds	$ 6,850	$ 100	$ 100
Underwritten public offering	$ 7,500
Shares of common stock (in Shares)	5,340,600
Warrants shares (in Shares)	2,670,300	293,042
Warrant shares of common stock (in Shares)	2
Exercisable price per share (in Dollars per share)	$ 1.57
Warrant per share (in Dollars per share)	$ 1.4

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Details)		12 Months Ended
Summary of Significant Accounting Policies (Details)	Jan. 01, 2022 USD ($)	Dec. 31, 2022 USD ($) shares	Dec. 31, 2021 USD ($)
Summary of Significant Accounting Policies (Details) [Line Items]
Number of segments		1
Insignificant		$ 277,000	$ 277,000
Institution total amount		$ 2,300,000
Redeemable convertible preferred stock (in Shares) \| shares		11,436,956
Operating lease liabilities		$ 166,000
Other current liabilities		$ 263,000
ROU [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Operating lease liabilities	$ 429,000
Operating lease right-of-use assets	$ 380,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	$ 8,171	$ 16,830
Total short-term investments		15,921
Money market funds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	8,171	16,830
Certificates of deposit [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		250
Commercial paper [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		2,210
Corporate notes [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		12,024
Municipal bonds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		1,437
Level 1 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	8,171	16,830
Total short-term investments
Level 1 [Member] \| Money market funds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents	8,171	16,830
Level 1 [Member] \| Certificates of deposit [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 1 [Member] \| Commercial paper [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 1 [Member] \| Corporate notes [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 1 [Member] \| Municipal bonds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 2 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Total short-term investments		15,921
Level 2 [Member] \| Money market funds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Level 2 [Member] \| Certificates of deposit [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		250
Level 2 [Member] \| Commercial paper [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		2,210
Level 2 [Member] \| Corporate notes [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		12,024
Level 2 [Member] \| Municipal bonds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments		1,437
Level 3 [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Total short-term investments
Level 3 [Member] \| Money market funds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total cash equivalents
Level 3 [Member] \| Certificates of deposit [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 3 [Member] \| Commercial paper [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 3 [Member] \| Corporate notes [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments
Level 3 [Member] \| Municipal bonds [Member]
Fair Value Measurements (Details) - Schedule of assets and liabilities that are measured at fair value [Line Items]
Total short-term investments

Cash, Cash Equivalents and Sh_3

Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of cash, cash equivalents and short-term investments - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Cash and cash equivalents:
Total cash and cash equivalents	$ 10,759	$ 17,675
Short-term investments:
Total short-term investments		15,921
Cash [Member]
Cash and cash equivalents:
Total cash and cash equivalents	2,588	845
Money market funds [Member]
Cash and cash equivalents:
Total cash and cash equivalents	8,171	16,830
Certificates of deposit [Member]
Short-term investments:
Total short-term investments		250
Commercial paper [Member]
Short-term investments:
Total short-term investments		2,210
Corporate notes [Member]
Short-term investments:
Total short-term investments		12,024
Municipal bonds [Member]
Short-term investments:
Total short-term investments		$ 1,437

Cash, Cash Equivalents and Sh_4

Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of short-term investments $ in Thousands	Dec. 31, 2021 USD ($)
Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of short-term investments [Line Items]
Amortized Cost	$ 15,932
Gross Unrealized Gains
Gross Unrealized Losses	(11)
Aggregate Estimated Fair Value	15,921
Certificates of Deposit [Member]
Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of short-term investments [Line Items]
Amortized Cost	250
Gross Unrealized Gains
Gross Unrealized Losses
Aggregate Estimated Fair Value	250
Commercial Paper [Member]
Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of short-term investments [Line Items]
Amortized Cost	2,210
Gross Unrealized Gains
Gross Unrealized Losses
Aggregate Estimated Fair Value	2,210
Corporate Notes [Member]
Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of short-term investments [Line Items]
Amortized Cost	12,035
Gross Unrealized Gains
Gross Unrealized Losses	(11)
Aggregate Estimated Fair Value	12,024
Municipal Bonds [Member]
Cash, Cash Equivalents and Short-Term Investments (Details) - Schedule of short-term investments [Line Items]
Amortized Cost	1,437
Gross Unrealized Gains
Gross Unrealized Losses
Aggregate Estimated Fair Value	$ 1,437

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	12 Months Ended
Property and Equipment (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Property and Equipment [Abstract]
Total depreciation and amortization expense	$ 147,000	$ 74,000

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 671	$ 630
Less: accumulated depreciation	(228)	(101)
Total property and equipment, net	443	529
Office equipment and furniture [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	263	237
Software [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	131	115
Test equipment [Member]
Property, Plant and Equipment [Line Items]
Total property and equipment	$ 277	$ 278

Other Current Liabilities (Deta

Other Current Liabilities (Details) - Schedule of other current liabilities - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Schedule of Other Current Liabilities [Abstract]
Accrued compensation	$ 2,708	$ 2,211
Accrued severance payment	517
Accrued research and development	536	289
Accrued vacation	243	276
Lease liabilities, current portion	212
Other	205	131
Total other current liabilities	$ 4,421	$ 2,907

Paycheck Protection Program L_2

Paycheck Protection Program Loan (Details) - USD ($)	Apr. 23, 2020	May 27, 2020
Paycheck Protection Program Loan (Details) [Line Items]
Unsecured loan	$ 351,000	$ 351,000
Interest rate	1%
Loan term	10 months
PPP Loan [Member]
Paycheck Protection Program Loan (Details) [Line Items]
Loan term	2 years

Convertible Promissory Notes (D

Convertible Promissory Notes (Details) - USD ($)	1 Months Ended	3 Months Ended	11 Months Ended	12 Months Ended
Convertible Promissory Notes (Details) - USD ($)	Mar. 31, 2021	Mar. 31, 2021	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2020
Convertible Promissory Notes (Details) [Line Items]
Convertible notes accrued interest				4%
Maturity date				Feb. 28, 2022
Convertible notes to nonemployees in exchange for services			$ 247,000	$ 747,000	$ 247,000
IssuanceOfStockAndWarrantsForServicesOrClaim					500,000
Debt value			747,000		747,000
Additional nonemployee services		$ 50,000
Issuance of convertible note		500,000
Shares issued (in Shares)				10,000
Warrants to purchase common stock (in Shares)				204,500
Common stock, per share (in Dollars per share)				$ 2.97
Warrants to purchase common stock were cancelled (in Shares)	42,220
Issuance costs				$ 83,000
Commissions				$ 612,000
Convertible note conversion, description				The Company determined that the terms that would result in Convertible Notes automatically converting at (i) 80% of the lowest per-share selling price of the stock sold by the Company in the Next Qualified Equity Financing or (ii) 80% of the lowest per-share selling price of the Conversion Stock sold by the Company in an IPO are deemed a redemption feature. The Company also concluded that those redemption features require bifurcation from the Convertible Notes and subsequent accounting in the same manner as a freestanding derivative.
Interest expense				$ 800,000
Aggregate amount				810,400
Change in fair value of derivative liability				100,000
IPO [Member]
Convertible Promissory Notes (Details) [Line Items]
Convertible notes for non-employee services	$ 500,000	500,000
Prepaid assets and other current expenses	$ 300,000	$ 300,000
Common stock equivalents				60,000,000
Outstanding principal				12,500,000
Interest due				400,000
Aggregate amount				$ 12,900,000
Converted shares (in Shares)				5,015,494
Conversion price per share (in Dollars per share)				$ 2.5736
Unamortized discount				$ 400,000
Unamortized discount related to BCF				$ 500,000
Convertible Notes Payable [Member]
Convertible Promissory Notes (Details) [Line Items]
Other noncurrent liabilities			150,000		$ 150,000
Convertible Debt [Member]
Convertible Promissory Notes (Details) [Line Items]
Total proceeds			$ 11,800,000

Convertible Promissory Notes _2

Convertible Promissory Notes (Details) - Schedule of convertible notes	12 Months Ended
	Dec. 31, 2022
Next Qualified Equity Financing [Member]
Convertible Promissory Notes (Details) - Schedule of convertible notes [Line Items]
Description	Upon the closing of a Next Qualified Equity Financing (defined as greater than $5,000,000), the Convertible Notes are converted into shares issued equal to the outstanding balance divided by the Conversion Price.
Conversion Price	An amount equal to the lower of (i) 80% of the lowest per-share selling price of such stock sold by the Company at the Next Qualified Equity Financing or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents (defined as fully diluted common shares for all outstanding securities, excluding common shares reserved for issuance or exercise of options or grants in the future) immediately prior to Next Qualified Equity Financing closing.
Change of Control [Member]
Convertible Promissory Notes (Details) - Schedule of convertible notes [Line Items]
Description	If at any time before payment or conversion of the balance, the Company effects a Change of Control, all of the balance outstanding immediately prior to such Change of Control will automatically convert into the most senior series of Preferred Stock outstanding immediately prior to such Change of Control at the Conversion Price.
Conversion Price	An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to such Change of Control.
Maturity Date [Member]
Convertible Promissory Notes (Details) - Schedule of convertible notes [Line Items]
Description	If the Company has not paid or otherwise converted the entire balance before the Maturity Date, then on the Maturity Date, all of the balance then outstanding will automatically convert into the most senior series of Preferred Stock outstanding as of the Maturity Date at the Conversion Price then in effect.
Conversion Price	An amount equal to the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents as of the Maturity Date.
Automatic Conversion – IPO [Member]
Convertible Promissory Notes (Details) - Schedule of convertible notes [Line Items]
Description	If at any time before payment or conversion of the balance, the Company consummates an IPO, all of the balance outstanding immediately prior to the IPO will automatically convert into Common Stock at the Conversion Price.
Conversion Price	An amount equal to the lower of (i) 80% of the lowest per-share selling price of the Common Stock sold by the Company in an IPO or (ii) the implied per share price determined by dividing $60,000,000 by the total number of Common Stock Equivalents immediately prior to closing of an IPO.
Optional Conversion [Member]
Convertible Promissory Notes (Details) - Schedule of convertible notes [Line Items]
Description	If at any time while the Convertible Notes are still outstanding the Company sells stock in a single transaction or in a series of related transactions that does not constitute a Next Qualified Equity Financing (and thus is defined as a Non-qualified Financing), then, at the closing of the Nonqualified Financing, the balance then outstanding may be converted, at the option of the holder, into that number of shares of Non-qualified Preferred Stock (preferred stock sold in the Non-qualified Financing) determined by dividing (i) the balance by (ii) the Conversion Price then in effect.
Conversion Price	An amount equal to the lowest per share selling price of Nonqualified Preferred Stock sold by the Company for new cash investment in the Non-Qualified Financing.

Convertible Promissory Notes _3

Convertible Promissory Notes (Details) - Schedule of fair value of the derivative liability $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Schedule Of Fair Value Of The Derivative Liability Abstract
Derivative liability, beginning balance	$ 121
Fair Value at issuance date
Change in fair value	(121)
Derivative liability, ending balance

Redeemable Convertible Prefer_2

Redeemable Convertible Preferred Stock (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 24, 2021	Dec. 31, 2022	Dec. 31, 2021
Redeemable Convertible Preferred Stock (Details) [Line Items]
Convertible common stock (in Shares)			11,436,956
Convertible preferred stock, description	the Company’s Third Amended and Restated Certificate of Incorporation was filed with the Delaware Secretary of State which (i) eliminated the Company’s Series A and Series B preferred stock, (ii) increased the authorized number of shares of common stock to 75,000,000 and (iii) authorized 5,000,000 shares of preferred stock at par value of $0.0001 per share.
Series B Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Transaction price net of issuance costs		$ 9.3
Accumulated accretion		11.5
Preferred stock carrying value		20.8
Series A Preferred Stock [Member]
Redeemable Convertible Preferred Stock (Details) [Line Items]
Accumulated accretion		8.2
Preferred stock carrying value		$ 14.5

Common Stock (Details)

Common Stock (Details) - USD ($)		1 Months Ended	12 Months Ended
Common Stock (Details) - USD ($)	Aug. 15, 2022	Mar. 25, 2021	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2018
Common Stock (Details) [Line Items]
Common stock, shares authorized			75,000,000	75,000,000
Common stock, par value (in Dollars per share)			$ 0.0001	$ 0.0001
Common stock, shares issued			33,659,460
Common stock, shares outstanding				32,772,060
Converted into shares				11,436,956
common stock vote			one
Shares of common stock for non-employee			17,000
Value of common stock issued for non-employee services (in Dollars)			$ 85,000,000
Aggregate offering price (in Dollars)	$ 50,000,000		47,700,000
Aggregate amount (in Dollars)			$ 810,400
Stock Option, Exercise Price, Increase (in Dollars per share)			$ 2.84
Purchase price per share (in Dollars per share)					$ 0.0125
Subject to the repurchase option				75,833
Early exercise of common stock option				50,000
Repurchase liability (in Dollars)			$ 136,000	$ 281,000
Shares remain unvested			266,147
Shares remain unvested				567,397
Weighted average vesting period			1 year 1 month 2 days
Common Stock [Member]
Common Stock (Details) [Line Items]
Converted into shares				5,015,494
Shares of common stock for non-employee			810,400
Received net proceeds (in Dollars)			$ 2,200,000
IPO [Member]
Common Stock (Details) [Line Items]
Common stock, shares authorized			75,000,000
Common stock, par value (in Dollars per share)			$ 0.0001
Aggregate amount (in Dollars)		$ 12,900,000
Converted into shares		5,015,494
Aggregate amount (in Dollars)			$ 12,900,000
Series A and Series B Redeemable Convertible Preferred Stock [Member]
Common Stock (Details) [Line Items]
Converted into shares of common stock		11,436,956
Restricted Stock [Member]
Common Stock (Details) [Line Items]
Shares of common stock for non-employee					3,640,000
Purchase price per share (in Dollars per share)			$ 0.0125
Founder [Member]
Common Stock (Details) [Line Items]
Shares of common stock for non-employee					400,000
Purchase price per share (in Dollars per share)				$ 0.0125
Subject to the repurchase option				8,333

Common Stock (Details) - Schedu

Common Stock (Details) - Schedule of common stock reserved for future issuance	Dec. 31, 2022 shares
Schedule Of Common Stock Reserved For Future Issuance Abstract
Warrants to purchase common stock	1,938,143
Stock options outstanding	6,919,894
Stock options available for future grants	6,711,065
Total	15,569,102

Common Stock Warrants (Details)

Common Stock Warrants (Details) - USD ($)	1 Months Ended		3 Months Ended	12 Months Ended
Common Stock Warrants (Details) - USD ($)	Feb. 28, 2021	Apr. 16, 2019	Mar. 31, 2021	Dec. 31, 2022	Dec. 31, 2021	Aug. 31, 2019	Aug. 28, 2019
Common Stock Warrants (Details) [Line Items]
Warrants issued, description				In connection with the closing of the Series A preferred stock offering, the Company issued warrants (“Preferred A Placement Warrants”) to purchase a total of 133,648 shares of its common stock to NSC on March 14, 2018 and April 23, 2018.
Total number of warrant shares increased						242,847
Exercise price (in Dollars per share)					$ 871,167
Conversion of shares					11,436,956
Warrants to purchase common stock				204,500
Warrants liabilities (in Dollars)				$ 3,100,000
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Common stock shares issued percentage				10%
Total number of warrant shares increased							242,847
Exercise price (in Dollars per share)							$ 1.4
Increasing number of warrants							109,200
Additional shares of common stock				50,195
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Common stock shares issued percentage		10%
Shares of common stock		414,270		49,528
Warrants term		5 years
Convertible Note Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Conversion price (in Dollars per share)				$ 2.57
Shares issued				10,000
Warrants to purchase common stock				204,050
Exercisable into common stock per share (in Dollars per share)				$ 2.97
Common stock cancelled (in Dollars)			$ 42,220
Underwriter Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Shares of common stock				956,973
Warrants term				5 years
Purchase shares percentage				9.79%
Warrant exercisable price per share (in Dollars per share)				$ 6
Series A Preferred Stock [Member]
Common Stock Warrants (Details) [Line Items]
Conversion of shares				1,336,485
Conversion price (in Dollars per share)				$ 1.4
Preferred A Lead Investor Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Warrants for common stock issued	52,500
Weighted average exercise price (in Dollars per share)	$ 0.0125
Series B Preferred Stock [Member]
Common Stock Warrants (Details) [Line Items]
Exercise price (in Dollars per share)		$ 2.1
Series B Preferred Stock [Member] \| Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) [Line Items]
Conversion of shares		4,142,270

Common Stock Warrants (Detail_2

Common Stock Warrants (Details) - Schedule of company's warrant activity - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Class of Warrant or Right [Line Items]
Warrant Issuance, Exercise Price (in Dollars per share)		$ 871,167
Warrant Issuance, Outstanding beginning	1,938,143	1,009,473
Warrant Issuance, Granted
Warrant Issuance, Exercised		(42,220)
Warrant Issuance, Canceled/ Expired		99,723
Warrant Issuance, Variable Settlement Provision Adjustment	1,938,143	1,938,143
Preferred A Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	March and April 2018 and August 2019	$1.40
Warrant Issuance, Exercise Price (in Dollars per share)	$ 1.4	$ 242,847
Warrant Issuance, Outstanding beginning	293,042
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired		50,195
Warrant Issuance, Variable Settlement Provision Adjustment	293,042	293,042
Warrant Issuance, Outstanding ending	March and April 2023	March and April 2023
Warrant Issuance, Expiration		Preferred A Placement Warrants
Preferred A Lead Investor Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	February 2021	$0.0125
Warrant Issuance, Exercise Price (in Dollars per share)	$ 0.0125
Warrant Issuance, Outstanding beginning	52,500	52,500
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	52,500	52,500
Warrant Issuance, Outstanding ending	March 2023	March 2023
Warrant Issuance, Expiration		Preferred A Lead Investor Warrants
Preferred B Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	April 2019	$2.10
Warrant Issuance, Exercise Price (in Dollars per share)	$ 2.1	$ 414,270
Warrant Issuance, Outstanding beginning	463,798
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired		49,528
Warrant Issuance, Variable Settlement Provision Adjustment	463,798	463,798
Warrant Issuance, Outstanding ending	April 2024	April 2024
Warrant Issuance, Expiration		Preferred B Placement Warrants
Convertible Notes Placement Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	August 2020	$2.57
Warrant Issuance, Exercise Price (in Dollars per share)	$ 2.57	$ 214,050
Warrant Issuance, Outstanding beginning	171,830
Warrant Issuance, Granted
Warrant Issuance, Exercised		(42,220)
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	171,830	171,830
Warrant Issuance, Outstanding ending	August 2025	August 2025
Warrant Issuance, Expiration		Convertible Notes Placement Warrants
Underwriter Warrants [Member]
Class of Warrant or Right [Line Items]
Warrant Issuance, Issuance	March 2021	$6.00
Warrant Issuance, Exercise Price (in Dollars per share)	$ 6
Warrant Issuance, Outstanding beginning	956,973	956,973
Warrant Issuance, Granted
Warrant Issuance, Exercised
Warrant Issuance, Canceled/ Expired
Warrant Issuance, Variable Settlement Provision Adjustment	956,973	956,973
Warrant Issuance, Outstanding ending	March 2026	March 2026
Warrant Issuance, Expiration		Underwriter Warrants

Common Stock Warrants (Detail_3

Common Stock Warrants (Details) - Schedule of changes in fair value of the outstanding warrants $ in Thousands	12 Months Ended
	Dec. 31, 2021 USD ($)
Common Stock Warrants (Details) - Schedule of changes in fair value of the outstanding warrants [Line Items]
Warrant Issuance, Warrant liability beginning	$ 1,549
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	1,581
Warrant Issuance, Reclassified to additional paid-in capital	(3,130)
Warrant Issuance, Warrant liability ending
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the outstanding warrants [Line Items]
Warrant Issuance, Warrant liability beginning	518
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	575
Warrant Issuance, Reclassified to additional paid-in capital	(1,093)
Warrant Issuance, Warrant liability ending
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the outstanding warrants [Line Items]
Warrant Issuance, Warrant liability beginning	708
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	800
Warrant Issuance, Reclassified to additional paid-in capital	(1,508)
Warrant Issuance, Warrant liability ending
Convertible Notes Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of changes in fair value of the outstanding warrants [Line Items]
Warrant Issuance, Warrant liability beginning	323
Warrant Issuance, Fair value of warrants granted
Warrant Issuance, Fair value of warrants exercised
Warrant Issuance, Change in fair value of warrants	206
Warrant Issuance, Reclassified to additional paid-in capital	(529)
Warrant Issuance, Warrant liability ending

Common Stock Warrants (Detail_4

Common Stock Warrants (Details) - Schedule of black-scholes option pricing model assumptions	12 Months Ended
	Dec. 31, 2022
Preferred A Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of black-scholes option pricing model assumptions [Line Items]
Warrant Issuance, Dividend Yield
Warrant Issuance, Expected Volatility	59.21%
Warrant Issuance, Risk-Free Interest Rate	0.14%
Warrant Issuance, Expected Life	2 years
Preferred B Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of black-scholes option pricing model assumptions [Line Items]
Warrant Issuance, Dividend Yield
Warrant Issuance, Expected Volatility	58.51%
Warrant Issuance, Risk-Free Interest Rate	0.30%
Warrant Issuance, Expected Life	3 years
Convertible Note Placement Warrants [Member]
Common Stock Warrants (Details) - Schedule of black-scholes option pricing model assumptions [Line Items]
Warrant Issuance, Dividend Yield
Warrant Issuance, Expected Volatility	52.28%
Warrant Issuance, Risk-Free Interest Rate	0.82%
Warrant Issuance, Expected Life	4 years 4 months 24 days

Common Stock Warrants (Detail_5

Common Stock Warrants (Details) - Schedule of fair value at issuance for warrants - Black Scholes Fair Value Assumptions [Member] $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Common Stock Warrants (Details) - Schedule of fair value at issuance for warrants [Line Items]
Issuance Date	March 2021
Fair Value (in Dollars)	$ 2,349
Dividend Yield
Expected Volatility	52.58%
Risk-Free Interest Rate	0.82%
Expected Life	5 years

Stock-Based Compensation (Detai

Stock-Based Compensation (Details)			1 Months Ended				12 Months Ended
Stock-Based Compensation (Details)	Mar. 25, 2021 shares	Nov. 18, 2019 shares	Jun. 30, 2023	Jun. 21, 2022 $ / shares shares	Apr. 15, 2022 shares	Sep. 15, 2021 shares	Dec. 31, 2022 USD ($) $ / shares shares	Dec. 31, 2021 USD ($) $ / shares shares
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued						2,000,000	150,200	50,200
Future grant shares							6,711,065
Fair value option shares							1,707,794
Fair value option vested (in Dollars) \| $							$ 3,200,000
Granted share				100,000
Exercise price per share (in Dollars per share) \| $ / shares								$ 871,167
Stock compensation expense (in Dollars) \| $							100,000
Compensation expense (in Dollars) \| $							$ 6,600,000
Weighted average period							2 years 7 months 6 days
2019 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Common stock, shares		4,000,000
Fair value percentage		110%
Exercise price percentage		10%
Contractual term		10 years
Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued					7,400,000
Minimum [Member] \| 2019 Equity Incentive Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value percentage		100%
Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued					13,400,000
Stock Options [Member]
Stock-Based Compensation (Details) [Line Items]
Fair value (in Dollars per share) \| $ / shares							$ 1.48	$ 2.54
Stock option exercised, shares							77,000	134,531
Stock options exercised (in Dollars) \| $							$ 31,000	$ 100,000
Fair value option shares								839,380
Fair value option vested (in Dollars) \| $								$ 700,000
IPO [Member] \| Minimum [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued	6,000,000
IPO [Member] \| Maximum [Member]
Stock-Based Compensation (Details) [Line Items]
Aggregate shares issued	7,400,000
Founder [Member]
Stock-Based Compensation (Details) [Line Items]
Exercise price per share (in Dollars per share) \| $ / shares				$ 5
Forecast [Member]
Stock-Based Compensation (Details) [Line Items]
Product units			20,000
2019 Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Future grant shares							5,424,815
2021 Employment Inducement Plan [Member]
Stock-Based Compensation (Details) [Line Items]
Future grant shares							1,286,250

Stock-Based Compensation (Det_2

Stock-Based Compensation (Details) - Schedule of stock option activity - USD ($)		12 Months Ended
	Dec. 31, 2020	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Stock Option Activity Abstract
Number of Options, Outstanding Beginning	3,188,011	5,592,137
Weighted Average Exercise Price, Outstanding Beginning	$ 0.66	$ 2.29
Weighted Average Remaining Life, Outstanding Beginning	9 years
Intrinsic Value, Outstanding Beginning	$ 8,155,000	$ 9,912,000
Number of Options, Outstanding Ending		6,919,894	5,592,137
Weighted Average Exercise Price, Outstanding Ending		$ 2.34	$ 2.29
Weighted Average Remaining Life, Outstanding Ending		8 years 2 months 12 days	8 years 7 months 6 days
Intrinsic Value, Outstanding Ending		$ 2,034,000	$ 9,912,000
Number of Options, Exercisable		3,762,779
Weighted Average Exercise Price, Exercisable		$ 1.74
Weighted Average Remaining Life, Exercisable		7 years 8 months 12 days
Intrinsic Value, Exercisable		$ 1,826
Number of Options, Vested and expected to vest		6,769,694
Weighted Average Exercise Price, Vested and expected to vest		$ 2.32
Weighted Average Remaining Life, Vested and expected to vest		8 years 2 months 12 days
Intrinsic Value, Vested and expected to vest		$ 1,988
Number of Options, Granted		2,525,000	2,684,500
Weighted Average Exercise Price, Granted		$ 2.77	$ 4.05
Number of Options, Exercised		(77,000)	(134,541)
Weighted Average Exercise Price, Exercised		$ 0.4	$ 0.56
Number of Options, Cancelled		(1,120,243)	(145,833)
Weighted Average Exercise Price, Cancelled		$ 3.15	$ 0.59

Stock-Based Compensation (Det_3

Stock-Based Compensation (Details) - Schedule of weighted average assumptions for fair value of options estimated	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Weighted Average Assumptions For Fair Value Of Options Estimated Abstract
Dividend yield
Expected volatility	61.97%	66.38%
Risk-free interest rate	2.78%	0.93%
Expected life	6 years 25 days	6 years 18 days

Stock-Based Compensation (Det_4

Stock-Based Compensation (Details) - Schedule of stock-based compensation expense to employees and non-employees - USD ($)	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 3,096	$ 1,854
Research and development [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	1,169	716
General and administrative [Member]
Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation	$ 1,927	$ 1,138

Commitments and Contingencies_2

Commitments and Contingencies (Details) - USD ($)			1 Months Ended			12 Months Ended
Commitments and Contingencies (Details) - USD ($)	Jan. 01, 2022	May 15, 2021	Jun. 23, 2022	Apr. 23, 2022	Apr. 15, 2021	Dec. 31, 2022	Dec. 31, 2021
Commitments and Contingencies Disclosure [Abstract]
Lease term		40 months	36 months
Base rent				$ 5,100	$ 14,000
Security deposit					$ 47,000
Additional security deposit				$ 5,500
ROU assets	$ 380,000
Corresponding lease liabilities	$ 429,000
Rent expense						$ 226,000	$ 154,000
Non-cancelable obligations descriptions						The Company also had $0.4 million of non-cancelable contractual commitments as of December 31, 2022, primarily related to its vendor arrangements. These commitments are generally due within one to ten months.

Commitments and Contingencies_3

Commitments and Contingencies (Details) - Schedule of components of lease expense and supplemental cash flow information $ in Thousands	12 Months Ended
	Dec. 31, 2022 USD ($)
Schedule Of Components Of Lease Expense And Supplemental Cash Flow Information Abstract
Right-of-use assets	$ 389
Operating lease liabilities - Short-term	212
Operating lease liabilities - Long-term	214
Lease Cost:
Operating lease cost	226
Other Information:
Cash paid for amounts included in the measurement of lease liabilities for the year ended	$ 209
Weighted average remaining lease term - operating leases (in years)	1 year 11 months 19 days
Average discount rate - operating lease	10%

Commitments and Contingencies_4

Commitments and Contingencies (Details) - Schedule of future minimum lease payments $ in Thousands	Dec. 31, 2022 USD ($)
Schedule Of Future Minimum Lease Payments Abstract
2023	$ 242
2024	203
2025	27
Total lease payments	472
Less: Interest	(46)
Total operating lease liability	$ 426

Income Taxes (Details)

Income Taxes (Details) - USD ($)	12 Months Ended
Income Taxes (Details) - USD ($)	Dec. 31, 2022	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Valuation allowance increased	$ 7,002,000	$ 4,034,000
Federal net operating loss carryforwards	48,500,000	37,400,000
Research and development credit carryforwards	1,179,000	565,000
California credit carryforwards	$ 1,066,000	640,000
Domestic expenses and for foreign expenses term	15 years
Stockholders stock percentage	50%
Uncertain tax position percentage	50%
Unrecognized tax benefit liabilities	$ 811,000	$ 487,000
Amortized over period	5 years

Income Taxes (Details) - Schedu

Income Taxes (Details) - Schedule of the effective tax rate of the company’s provision (benefit) for income taxes differs from the federal rate	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of The Effective Tax Rate Of The Company SProvision Benefit For Income Taxes Differs From The Federal Rate Abstract
At Statutory rate	21%	21%
Valuation allowance	(22.00%)	(18.00%)
Changes in stock-based compensation, fair value of warrants and derivative liability and interest expense for convertible promissory notes	(1.00%)	(3.00%)
Other	1%	1%
Effective tax rate

Income Taxes (Details) - Sche_2

Income Taxes (Details) - Schedule of significant components of the company’s deferred tax assets and liabilities - USD ($) $ in Thousands	Dec. 31, 2022	Dec. 31, 2021
Gross deferred tax assets:
Net operating loss carryforwards	$ 10,040	$ 7,765
Research and development credit carryforward	1,434	712
Capitalized research and development	3,444
Accrued bonus	464	403
Stock-based compensation	590	72
Lease liabilities	90
Other	53	76
Total gross deferred tax assets	16,115	9,029
Less valuation allowance	(16,024)	(9,022)
Total net deferred tax assets	91	7
Deferred tax liabilities:
Property and equipment	(9)	(7)
Right-of-use assets	(82)
Total deferred tax liabilities	(91)	(7)
Net deferred tax assets

Income Taxes (Details) - Sche_3

Income Taxes (Details) - Schedule of rollforward of the total gross unrecognized tax benefits - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Rollforward Of The Total Gross Unrecognized Tax Benefits Abstract
Beginning Balance	$ 487	$ 289
Gross Increases - Tax Position in Prior Periods	1
Gross Increases - Tax Position in Current Period	323	198
Ending Balance	$ 811	$ 487

Net Loss Per Share Attributab_3

Net Loss Per Share Attributable to Common Stockholders (Details) - shares	1 Months Ended	12 Months Ended
	Sep. 15, 2021	Dec. 31, 2022	Dec. 31, 2021
Earnings Per Share [Abstract]
Performance based option shares	2,000,000	150,200	50,200

Net Loss Per Share Attributab_4

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Numerator:
Net loss	$ (30,329)	$ (21,773)
Accretion and dividends on redeemable convertible preferred stock		(2,489)
Net loss attributable to common stockholders	$ (30,329)	$ (24,262)
Denominator:
Weighted-average common shares outstanding (in Shares)	33,025,721	26,298,032
Net loss per share attributable to common stockholders, basic and diluted (in Dollars per share)	$ (0.92)	$ (0.92)

Net Loss Per Share Attributab_5

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of basic and diluted net loss per share attributable to common stockholders (Parentheticals) - $ / shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Basic And Diluted Net Loss Per Share Attributable To Common Stockholders Abstract
Net loss per share attributable to common stockholders diluted	$ (0.91)	$ (0.92)

Net Loss Per Share Attributab_6

Net Loss Per Share Attributable to Common Stockholders (Details) - Schedule of diluted net loss per share attributable to common stockholders - shares	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021
Schedule Of Diluted Net Loss Per Share Attributable To Common Stockholders Abstract
Non-vested shares under restricted stock grants		84,167
Shares subject to options to purchase common stock	6,769,694	5,541,937
Shares subject to warrants to purchase common stock	1,938,143	1,938,143
Total	8,707,837	7,564,247

Subsequent Events (Details)

Subsequent Events (Details)		1 Months Ended				12 Months Ended
Subsequent Events (Details)	Feb. 06, 2023 USD ($) $ / shares shares	Mar. 31, 2023 USD ($) $ / shares $ / item shares	Feb. 28, 2023 USD ($) $ / shares $ / item shares	Jan. 31, 2023 USD ($) $ / shares shares	Mar. 25, 2021 USD ($)	Dec. 31, 2022 shares	Dec. 31, 2021 $ / shares shares	Dec. 31, 2018 $ / shares
Subsequent Events (Details) [Line Items]
Exercisable price per share (in Dollars per share) \| $ / shares								$ 0.0125
Warrant per share (in Dollars per share) \| $ / shares							$ 871,167
Net proceeds (in Dollars) \| $					$ 44,300,000
Total shares						2,525,000	2,684,500
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Underwritten public offering (in Dollars) \| $	$ 7,500,000
Shares of common stock	5,340,600
Warrants shares	2,670,300		293,042
Warrant shares of common stock	2
Exercisable price per share (in Dollars per share) \| $ / shares	$ 1.57
Warrants expire term	5 years
Redemption price per warrant (in Dollars per share) \| $ / shares	$ 0.025
Subsequent event, description	(i) the closing price of the Company’s common stock has equaled or exceeded $4.87 per share for ten consecutive trading days and (ii) the daily trading volume of the common stock on the Company’s primary trading market exceeded 100,000 shares on each of such ten trading days.		The amended maturity dates for 234,197 and 58,845 Preferred A Placement Warrants will be in September 2023 and October 2023, respectively.
Warrant per share (in Dollars per share) \| $ / shares	$ 1.4
Net proceeds (in Dollars) \| $	$ 6,850,000		$ 100,000	$ 100,000
Shares of granted common stock option awards			60,000
Exercise price (in Dollars per Item) \| $ / item			1.37
Shares of common stock option			245,855	245,855
Weighted average exercise price (in Dollars per share) \| $ / shares			$ 0.44	$ 0.44
Sold shares		2,070,616
Weighted average price per share (in Dollars per share) \| $ / shares		$ 1.36
Executive Employees [Member] \| Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Exercise price (in Dollars per Item) \| $ / item		662,500
Non Executive Employees [Member] \| Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Exercise price (in Dollars per Item) \| $ / item		1.29
Subsequent Event [Member]
Subsequent Events (Details) [Line Items]
Warrants shares		52,500
Equity offering program for gross proceeds (in Dollars) \| $		$ 2.8
Subsequent Event [Member] \| Executive Employees [Member]
Subsequent Events (Details) [Line Items]
Total shares		562,875